

Table of Contents

Section I: Patient Survival

- I.1 Incident Patient Counts: ESRD Patients
by Age, Gender, Race, Ethnicity, & Primary Diagnosis
- I.2 One-year Survival Probabilities: Incident ESRD Patients
From Day 91 to One year + 90 Days by Age, Gender, Race, Ethnicity, & Primary Diagnosis
- I.3 Two-year Survival Probabilities: Incident ESRD Patients
From Day 91 to Two Years + 90 Days, by Age, Gender, Race, Ethnicity, & Primary Diagnosis
- I.4 Five-year Survival Probabilities: Incident ESRD Patients
From Day 91 to Five Years + 90 Days, by Age, Gender, Race, Ethnicity, & Primary Diagnosis
- I.5 Ten-year Survival Probabilities: Incident ESRD Patients
From Day 91 to Ten Years + 90 Days, by Age, Gender, Race, & Primary Diagnosis
- I.6 Incident Patient Counts: ESRD Patients Aged 65 & Over
Patients Aged 65 & Over on Day 1, by Age, Gender, Race, Ethnicity, & Primary Diagnosis
- I.7 One-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over
From Day 1 to One year, by Age, Gender, Race, Ethnicity, & Primary Diagnosis
- I.8 Two-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over
From Day 1 to Two Years, by Age, Gender, Race, Ethnicity, & Primary Diagnosis
- I.9 Five-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over
From Day 1 to Five Years, by Age, Gender, Race, Ethnicity, & Primary Diagnosis
- I.10 Ten-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over
From Day 1 to Ten Years, by Age, Gender, Race, & Primary Diagnosis
- I.11 Incident Patient Counts: Dialysis Patients
Dialysis Patients alive on Day 91, by Age, Gender, Race, Ethnicity, & Primary Diagnosis
- I.12 One-year Survival Probabilities: Incident Dialysis Patients
Censored at Transplant, From Day 91 to One year + 90 Days, by Age, Gender, Race, Ethnicity, & Primary Diagnosis
- I.13 Two-year Survival Probabilities: Incident Dialysis Patients
Censored at Transplant, From Day 91 to Two Years + 90 Days, by Age, Gender, Race, Ethnicity, & Primary Diagnosis
- I.14 Five-year Survival Probabilities: Incident Dialysis Patients
Censored at Transplant, From Day 91 to Five Years + 90 Days, by Age, Gender, Race, Ethnicity, & Primary Diagnosis
- I.15 Ten-year Survival Probabilities: Incident Dialysis Patients
Censored at Transplant, From Day 91 to Ten Years + 90 Days, by Age, Gender, Race, & Primary Diagnosis

Table I.1
Incident Patient Counts: ESRD Patients
by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	41	60	87	99	97	119	118	112	118	120	102	133	120	128	98	118	124	107	91	94	123	116
5-9	87	79	99	84	94	91	112	99	80	100	107	100	91	95	122	97	95	80	85	91	88	89
10-14	161	166	200	181	211	192	188	189	181	166	174	201	195	198	206	205	204	187	178	176	196	176
15-19	396	428	410	401	377	389	405	430	428	456	420	389	436	430	405	431	427	351	383	389	365	386
20-29	1,380	1,544	1,729	1,669	1,802	1,873	1,938	1,913	2,033	2,176	2,179	2,213	2,283	2,265	2,179	2,083	2,095	1,948	1,979	1,861	1,918	1,958
30-39	2,027	2,299	2,543	2,625	2,813	2,986	3,341	3,362	3,689	4,012	4,150	4,337	4,620	4,554	4,689	4,531	4,494	4,231	4,213	4,295	4,162	4,186
40-49	2,268	2,548	2,662	2,967	3,102	3,377	3,653	4,065	4,418	5,033	5,387	6,073	6,481	6,726	6,937	7,289	7,633	7,372	7,909	7,895	8,141	8,135
50-59	3,422	4,036	4,335	4,430	4,688	4,989	5,281	5,655	6,312	6,807	7,233	7,816	8,653	8,928	9,893	9,905	10,271	10,974	11,737	12,440	12,829	13,483
60-64	1,911	2,190	2,464	2,881	3,168	3,508	3,637	4,081	4,446	4,821	5,192	5,745	6,020	6,224	6,449	6,681	6,957	7,120	7,475	7,628	7,908	8,160
65-69	1,946	1,990	2,276	3,032	3,097	3,505	4,027	4,598	5,102	5,893	6,550	7,271	7,839	8,132	8,688	8,682	9,474	9,761	10,015	10,087	10,112	10,340
70-79	2,150	2,339	2,889	4,122	4,269	4,970	5,723	6,557	7,211	8,538	9,541	11,208	12,504	13,100	14,632	15,040	16,941	18,107	19,080	20,215	20,562	20,656
80+	358	389	536	841	904	1,128	1,371	1,605	1,936	2,399	2,778	3,243	3,801	4,109	4,645	5,027	6,030	6,824	7,499	8,437	9,083	9,485
Male	9,021	9,990	11,138	12,810	13,611	14,736	16,292	17,703	19,374	21,950	23,661	26,124	28,147	29,440	31,297	31,861	34,788	35,865	37,789	39,650	40,659	41,720
Female	7,126	8,078	9,092	10,522	11,011	12,391	13,502	14,963	16,580	18,571	20,152	22,605	24,896	25,449	27,646	28,228	29,957	31,197	32,855	33,958	34,828	35,450
White	10,328	11,825	13,803	15,455	16,455	18,168	20,073	21,786	23,816	26,825	29,202	32,386	35,021	36,061	38,646	38,668	41,918	43,849	45,866	48,462	50,073	50,973
Black	5,241	5,643	5,868	7,133	7,322	7,988	8,635	9,667	10,755	12,329	13,035	14,561	16,027	16,635	17,726	18,076	19,319	19,717	20,888	21,102	21,269	21,913
Other race	578	600	559	744	845	971	1,086	1,213	1,383	1,367	1,576	1,782	1,995	2,193	2,571	3,345	3,508	3,496	3,890	4,044	4,145	4,284
†Hispanic																7,138	7,157	7,599	8,115	8,648	8,853	
†Non-Hispanic																57,607	59,905	63,045	65,493	66,839	68,317	
Diabetes	2,438	3,569	4,720	5,484	6,617	7,632	8,805	9,917	11,256	13,601	15,380	17,607	19,544	20,464	22,764	25,301	28,527	30,125	31,836	33,508	34,840	35,743
Hypertension	2,717	3,920	4,981	5,530	6,139	7,040	7,709	8,789	10,037	11,576	12,750	14,067	15,601	16,045	17,163	15,823	17,177	18,300	18,964	20,000	20,235	20,876
Glomerulonephritis	2,319	2,948	3,518	3,771	4,049	4,258	4,291	4,656	4,917	5,189	5,495	5,807	6,000	6,090	6,433	6,691	7,007	6,557	6,934	6,737	6,486	6,395
Cystic kidney	684	842	967	983	1,001	1,046	1,154	1,182	1,197	1,176	1,298	1,398	1,432	1,490	1,459	1,653	1,576	1,573	1,653	1,735	1,731	1,783
Other urologic	380	492	494	560	578	706	698	676	727	759	765	882	928	807	788	1,008	1,267	1,184	1,204	1,325	1,298	1,309
Other cause	1,807	2,388	3,033	3,230	3,353	3,632	3,886	4,040	4,111	4,668	4,532	4,916	5,273	5,306	5,692	6,759	6,630	6,783	7,270	7,415	7,744	7,884
Unknown cause	1,586	1,835	1,719	1,851	1,989	2,099	2,494	2,790	2,928	3,019	3,197	3,703	3,984	4,267	4,441	2,696	2,433	2,431	2,631	2,681	2,907	3,014
Missing cause	4,216	2,074	798	1,923	896	714	757	616	781	533	396	349	281	420	203	158	128	109	152	207	246	166
All	16,147	18,068	20,230	23,332	24,622	27,127	29,794	32,666	35,954	40,521	43,813	48,729	53,043	54,889	58,943	60,089	64,745	67,062	70,644	73,608	75,487	77,170

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.
The age of the incident patient is determined as of the date of ESRD initiation.
Patients of unknown age, gender, race, or primary diagnosis are excluded.
†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.2
One-year Survival Probabilities: Incident ESRD Patients

from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	92.7	91.7	88.5	88.9	86.6	89.9	93.2	91.1	80.5	84.2	82.4	85.0	91.7	89.1	91.8	86.4	94.4	89.7	90.1	91.5	87.0	89.5
5-9	93.1	96.2	94.9	97.6	94.7	94.5	98.2	99.0	100.0	98.0	97.2	98.0	97.8	96.8	100.0	97.9	96.8	95.0	100.0	98.9	98.9	96.6
10-14	98.1	97.6	98.5	97.8	97.2	97.4	98.9	98.4	96.1	94.6	96.6	97.5	95.4	96.0	99.5	98.5	98.0	97.9	97.8	97.7	97.4	98.3
15-19	96.2	95.8	95.9	95.0	96.3	95.9	95.6	95.8	97.4	98.7	97.1	96.1	96.6	96.7	96.0	98.1	96.7	98.3	96.3	98.5	97.3	98.2
20-29	91.4	93.2	93.3	93.4	93.3	92.3	94.2	92.3	93.0	93.0	93.3	92.8	94.0	93.7	93.9	93.4	95.2	96.2	96.0	95.9	94.1	95.3
30-39	89.0	89.0	88.9	89.9	88.6	89.0	89.6	89.0	90.1	89.6	90.5	90.0	90.7	90.1	90.6	90.6	91.1	92.2	91.8	92.0	92.2	92.1
40-49	87.9	87.0	86.6	87.6	87.6	87.5	87.5	87.9	88.7	88.5	89.2	88.1	88.7	89.6	89.6	89.8	90.1	90.5	89.6	90.2	90.5	90.1
50-59	83.0	83.2	83.9	81.5	81.9	81.9	82.6	83.0	83.5	83.0	84.3	84.1	85.2	85.2	86.1	86.4	85.7	86.1	85.9	86.3	85.9	86.7
60-64	77.8	77.2	77.4	77.0	75.5	76.1	76.8	76.0	76.4	77.4	78.4	79.0	79.5	81.2	81.0	80.5	81.9	82.1	80.5	81.5	81.3	82.0
65-69	73.0	73.5	73.6	72.0	72.7	71.1	73.1	73.1	73.2	73.8	75.4	75.0	75.4	77.2	76.3	77.1	77.8	77.0	76.2	76.5	77.0	77.0
70-79	66.8	68.0	68.2	65.2	66.2	66.6	66.3	65.4	66.1	67.3	68.3	68.1	68.4	69.8	70.1	70.2	70.8	69.8	69.8	69.5	69.4	69.6
80+	58.7	54.2	62.9	54.9	56.6	58.0	58.9	55.4	55.7	57.6	59.4	59.1	58.4	61.0	61.0	60.4	60.3	59.4	57.5	58.2	57.8	57.9
Male	80.9	81.7	81.2	78.7	78.8	78.4	78.3	78.0	77.7	78.3	79.1	78.4	78.6	79.9	79.4	79.4	79.5	78.8	78.1	78.3	78.0	78.4
Female	81.6	81.2	81.6	79.1	79.3	78.8	79.6	78.0	78.9	78.4	79.0	78.3	78.7	79.1	79.3	79.2	78.9	78.1	77.3	77.0	77.0	77.0
White	80.5	80.6	80.1	77.4	77.1	76.9	77.2	76.0	76.1	76.2	76.8	76.0	76.1	77.2	77.1	77.1	76.8	75.8	75.4	75.3	75.2	75.1
Black	82.6	83.6	84.1	82.0	83.5	82.0	82.7	82.7	82.8	82.4	83.6	82.9	83.6	83.9	83.5	83.3	83.8	83.8	82.4	82.3	82.0	82.5
Other race	80.6	79.3	84.4	80.6	78.3	80.5	80.4	76.3	79.9	83.7	84.0	85.5	83.9	85.4	84.9	83.3	82.8	82.8	81.1	82.4	83.0	84.7
†Hispanic																	82.8	82.4	82.6	82.4	83.2	82.9
†Non-Hispanic																	78.8	78.1	77.2	77.2	76.8	77.1
Diabetes	75.3	73.8	73.4	73.5	74.1	73.6	75.2	74.9	76.1	76.6	76.7	77.0	77.1	78.9	78.9	78.5	78.6	78.0	77.0	77.6	77.6	77.9
Hypertension	83.4	81.6	79.8	78.0	77.4	78.2	77.5	75.9	76.3	76.3	77.4	76.4	76.6	77.2	77.1	77.8	77.9	76.6	76.0	75.8	75.8	75.7
Glomerulonephritis	91.3	89.2	88.6	87.3	87.6	87.5	86.3	86.4	86.7	86.7	86.8	85.9	87.6	88.4	87.2	87.8	88.1	87.6	87.8	87.4	87.4	87.7
Other cause	79.4	82.0	84.3	79.2	80.0	78.8	80.1	79.0	78.6	78.6	80.4	79.2	79.4	79.3	79.2	78.2	77.5	77.8	76.7	76.1	75.2	75.9
All	81.2	81.5	81.4	78.9	79.0	78.5	78.9	78.0	78.3	78.3	79.0	78.4	78.7	79.5	79.4	79.3	79.2	78.5	77.8	77.7	77.5	77.8
ADJUSTED																						
0-19	93.0	92.8	92.2	91.6	91.3	91.7	93.7	93.3	91.4	92.8	91.8	91.3	92.8	92.3	94.8	94.1	94.5	94.3	94.0	95.8	93.0	94.5
20-44	87.8	88.3	88.6	89.2	88.8	88.7	89.3	88.8	89.9	89.3	90.2	89.4	90.1	89.9	90.6	90.4	91.4	92.0	91.5	91.8	91.8	91.9
45-64	79.2	79.5	80.4	79.3	79.3	79.6	80.6	80.6	81.2	81.9	83.0	83.1	84.0	84.9	85.3	85.5	85.8	86.3	85.5	86.1	86.0	86.4
65-74	69.4	70.1	71.7	68.6	69.6	68.6	70.0	70.1	70.7	71.4	73.0	72.7	73.3	75.2	74.4	75.3	76.1	75.3	75.0	75.3	75.3	75.4
75+	60.3	61.7	61.8	58.3	60.5	61.9	61.9	59.2	59.8	62.0	63.1	63.1	62.6	64.0	64.9	64.5	64.8	63.9	63.1	63.2	63.0	63.3
Male	72.0	73.0	73.2	71.7	72.1	72.2	72.9	72.8	73.0	74.4	75.7	75.6	76.2	77.8	77.8	77.9	78.8	78.7	78.2	78.9	78.6	79.0
Female	73.5	73.5	75.2	73.7	74.2	74.3	75.8	74.8	76.1	76.3	77.5	77.3	77.9	78.6	79.1	79.5	79.7	79.4	78.8	78.7	78.9	79.0
White	70.8	71.1	71.9	70.2	70.4	70.9	72.0	71.5	72.3	73.4	74.6	74.4	75.0	76.5	76.9	77.3	77.8	77.5	77.3	77.6	77.6	77.6
Black	77.2	77.6	78.4	77.3	78.8	77.5	78.6	78.9	78.9	78.7	80.4	80.1	80.8	81.3	81.2	81.1	82.0	82.2	80.8	80.8	80.6	81.2
Other race	72.0	71.8	76.6	74.8	72.2	75.8	76.9	72.5	76.9	81.3	82.2	83.9	82.2	84.3	83.9	83.1	83.0	83.4	81.5	83.4	83.7	85.1
Diabetes	67.5	66.0	66.4	67.1	68.2	67.9	70.5	70.6	72.4	73.5	74.1	74.8	75.3	77.4	77.7	77.6	78.1	77.9	77.1	77.9	77.9	78.3
Hypertension	79.4	78.3	77.4	76.5	76.2	77.7	77.7	76.6	77.1	77.6	79.0	78.5	78.6	79.5	79.6	80.4	80.9	80.0	79.8	79.7	79.8	79.7
Glomerulonephritis	84.2	81.7	81.2	80.3	81.1	81.9	80.4	80.8	80.9	81.9	82.1	81.3	83.5	84.6	83.8	84.3	85.3	85.0	84.9	85.0	85.0	84.8
Other cause	74.3	75.8	78.8	75.6	75.7	74.4	75.9	75.1	74.8	75.0	77.1	76.2	76.7	76.5	76.9	76.1	75.7	76.6	75.4	75.3	74.5	75.1
All	72.7	73.2	74.2	72.6	73.1	73.2	74.3	73.8	74.5	75.3	76.6	76.4	77.0	78.2	78.4	78.7	79.3	79.1	78.5	78.8	78.8	79.0

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, race, or primary diagnosis are excluded. Includes U.S. & territories; no unknown or foreign states. †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Standard Errors

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	4.0	3.5	3.4	3.1	3.4	2.7	2.3	2.7	3.6	3.3	3.8	3.1	2.5	2.7	2.8	3.1	2.1	2.9	3.1	2.9	3.0	2.9
5-9	2.7	2.1	2.2	1.7	2.3	2.4	1.2	1.0	0.0	1.4	1.6	1.4	1.5	1.8	0.0	1.4	1.8	2.4	0.0	1.1	1.1	1.9
10-14	1.1	1.2	0.9	1.1	1.1	1.1	0.7	0.9	1.4	1.8	1.4	1.1	1.5	1.4	0.5	0.8	1.0	1.1	1.1	1.1	1.1	1.0
15-19	1.0	1.0	1.0	1.1	1.0	1.0	1.0	1.0	0.8	0.5	0.8	1.0	0.9	0.9	1.0	0.6	0.9	0.7	1.0	0.6	0.9	0.7
20-29	0.8	0.6	0.6	0.6	0.6	0.6	0.5	0.6	0.6	0.5	0.6	0.5	0.6	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.5	0.5
30-39	0.7	0.7	0.6	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
40-49	0.7	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
50-59	0.6	0.6	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3
60-64	1.0	0.9	0.8	0.8	0.8	0.7	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4
65-69	1.0	1.0	0.9	0.8	0.8	0.8	0.7	0.7	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4
70-79	1.0	1.0	0.9	0.7	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
80+	2.6	2.5	2.1	1.7	1.6	1.5	1.3	1.2	1.1	1.0	0.9	0.9	0.8	0.8	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5
Male	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Female	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
White	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Black	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Other race	1.6	1.7	1.5	1.4	1.4	1.3	1.2	1.2	1.1	1.0	0.9	0.8	0.8	0.8	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6
†Hispanic	0.4	0.5	0.4	0.4	0.4	0.4
†Non-Hispanic	0.2	0.2	0.2	0.2	0.2	0.2
Diabetes	0.9	0.7	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2
Hypertension	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Glomerulonephritis	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Other cause	0.4	0.4	0.4	0.4	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
All	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
ADJUSTED																						
0-19	1.3	1.2	1.4	1.3	1.6	1.4	1.2	1.2	1.3	1.2	1.2	1.4	1.2	1.2	1.0	1.1	1.0	1.1	1.2	0.9	1.3	1.1
20-44	0.5	0.5	0.4	0.5	0.4	0.4	0.4	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
45-64	0.6	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2
65-74	0.8	0.8	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
75+	1.4	1.4	1.2	1.1	1.0	0.8	0.7	0.7	0.7	0.6	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Male	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.4	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Female	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
White	0.6	0.5	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Black	0.7	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Other race	2.3	2.1	2.3	1.7	1.8	1.5	1.3	1.4	1.3	1.1	1.0	0.9	1.0	0.8	0.7	0.6	0.6	0.6	0.6	0.5	0.6	0.5
Diabetes	1.0	0.9	0.7	0.7	0.6	0.5	0.5	0.5	0.5	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.2
Hypertension	0.8	0.6	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.3	0.2	0.2	0.2
Glomerulonephritis	1.0	0.9	0.9	0.8	0.8	0.7	0.7	0.7	0.7	0.6	0.6	0.5	0.6	0.5	0.5	0.5	0.4	0.5	0.5	0.5	0.5	0.5
Other cause	0.5	0.6	0.5	0.5	0.5	0.5	0.4	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.4	0.3
All	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1

Table I.3
Two-year Survival Probabilities: Incident ESRD Patients
from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	85.4	90.0	83.9	81.8	83.5	84.0	87.3	84.8	75.4	79.2	77.5	81.2	89.2	85.2	85.7	83.1	90.3	86.0	86.8	88.3	82.9
5-9	92.0	92.4	92.9	94.0	92.6	93.4	93.8	97.0	97.5	97.0	94.4	98.0	97.8	92.6	97.5	96.9	95.8	93.8	97.6	97.8	98.9
10-14	95.7	94.6	96.5	96.7	95.3	95.3	95.7	98.4	95.0	92.8	94.3	96.5	93.8	93.4	98.1	96.6	96.6	96.8	97.2	97.2	96.2
15-19	94.7	92.5	93.2	92.3	93.1	94.1	92.8	94.2	94.6	96.9	95.0	93.3	95.0	94.7	94.8	96.8	93.2	95.2	94.0	95.4	94.3
20-29	85.8	87.2	88.3	87.1	87.6	86.4	88.5	85.8	88.2	88.6	88.0	87.8	89.1	89.5	90.0	88.7	91.1	91.7	92.5	91.5	89.7
30-39	80.2	81.3	80.1	82.0	79.9	79.9	81.1	80.7	82.7	82.0	82.6	81.8	82.6	83.3	82.6	83.9	84.4	85.4	84.8	85.9	86.0
40-49	77.0	76.4	76.4	76.0	77.2	77.6	76.9	77.7	78.6	78.2	80.0	77.6	79.4	80.1	80.1	80.8	80.5	81.4	81.2	81.1	81.5
50-59	70.2	70.2	70.5	68.1	67.3	67.3	68.2	68.2	68.9	70.1	70.5	70.8	72.0	72.9	73.9	73.4	73.4	74.1	73.1	74.1	74.1
60-64	62.9	60.7	60.6	61.1	58.6	58.7	60.2	59.1	60.0	61.0	61.6	62.5	62.9	65.3	65.6	64.9	66.7	66.7	65.2	67.0	67.4
65-69	54.9	55.8	55.1	52.2	55.1	52.9	53.9	55.5	55.8	55.9	56.4	56.8	57.9	60.1	58.9	59.8	60.9	59.5	59.4	59.9	61.1
70-79	46.6	48.7	48.9	44.1	46.5	46.9	46.5	45.6	46.5	47.6	47.9	48.1	49.1	50.0	50.3	50.7	51.7	49.9	50.9	51.0	50.6
80+	31.6	34.7	38.2	30.0	36.4	35.9	35.3	33.1	33.3	37.4	36.9	35.9	36.5	37.6	38.6	38.4	38.5	37.0	37.0	37.1	37.2
Male	67.3	68.6	67.9	64.2	64.7	63.2	63.8	63.0	63.4	63.9	64.0	63.3	63.9	65.4	64.8	65.0	64.8	63.6	63.5	63.7	63.8
Female	69.0	68.4	68.1	64.4	65.1	65.0	64.4	63.4	64.1	64.0	63.7	63.0	63.8	64.0	64.1	63.8	63.9	62.6	62.1	62.0	61.8
White	67.1	67.6	66.3	62.4	62.6	62.1	61.9	60.9	60.6	60.9	60.7	59.8	60.3	61.0	60.8	60.8	60.5	59.1	59.4	59.4	59.2
Black	69.7	70.9	71.6	68.2	70.2	68.4	69.4	68.5	70.5	70.0	70.4	69.3	70.6	71.9	71.4	71.2	71.7	71.1	69.7	69.6	69.8
Other race	68.9	64.5	71.7	66.5	64.0	63.5	63.2	61.5	65.1	70.6	69.5	73.2	71.8	72.9	72.4	69.8	69.4	69.3	67.0	70.0	70.6
†Hispanic																	68.9	68.4	69.1	69.6	71.7
†Non-Hispanic																	63.8	62.5	62.1	62.1	61.7
Diabetes	57.7	56.1	54.6	56.3	54.9	55.4	56.6	56.7	58.2	59.4	58.4	58.9	59.7	61.6	61.7	61.2	61.4	60.6	60.1	61.1	61.4
Hypertension	71.3	68.0	66.1	62.8	63.8	62.8	62.2	60.5	61.8	61.4	61.4	60.5	61.4	61.8	62.1	62.7	62.9	60.9	60.5	60.4	60.5
Glomerulonephritis	82.6	79.7	79.0	77.1	78.1	76.9	75.7	75.8	77.1	76.4	76.9	75.5	77.4	78.9	77.2	78.2	78.3	77.2	78.7	77.8	78.2
Other cause	66.1	70.4	72.9	64.8	67.3	66.5	67.5	66.4	65.4	66.7	68.2	66.6	67.1	66.9	66.2	65.7	65.3	65.1	64.6	63.7	62.9
All	68.0	68.6	68.0	64.3	64.9	64.0	64.1	63.2	63.8	64.0	63.9	63.1	63.9	64.8	64.5	64.4	64.4	63.1	62.9	62.9	62.8
ADJUSTED																					
0-19	89.6	87.6	87.7	86.6	86.8	87.8	87.9	90.1	87.0	89.4	87.6	87.7	90.3	88.0	91.4	91.2	89.9	90.3	90.8	92.2	89.2
20-44	77.6	79.4	79.7	80.0	79.9	79.6	80.6	79.9	81.9	81.6	82.3	80.9	82.1	82.4	83.0	83.1	84.2	85.2	84.6	85.0	85.1
45-64	64.8	64.3	65.3	64.3	63.6	64.1	65.4	65.3	66.3	68.0	68.8	69.1	70.3	72.0	72.6	72.7	73.4	73.9	73.1	74.2	74.4
65-74	49.4	51.4	52.5	47.8	51.0	49.6	50.5	51.4	52.5	53.0	53.6	54.0	55.4	56.8	56.3	57.7	58.5	57.2	57.8	58.3	58.6
75+	37.7	41.0	39.7	35.3	39.5	40.5	39.9	37.8	38.3	41.6	41.4	41.3	41.6	42.9	43.6	43.2	44.4	42.7	43.2	43.3	43.3
Male	54.5	56.0	56.1	54.0	55.1	54.5	56.0	55.6	56.8	58.4	59.1	59.1	60.3	62.3	62.3	62.9	63.8	63.5	63.7	64.5	64.8
Female	57.4	57.4	58.7	56.6	57.9	58.6	58.9	59.0	60.1	61.1	61.6	61.6	62.8	63.4	64.0	64.3	65.2	64.6	64.4	64.7	64.7
White	53.2	54.3	54.4	52.4	53.4	53.8	54.5	54.7	55.4	57.1	57.6	57.7	58.9	60.1	60.6	61.3	62.2	61.7	62.4	62.9	63.0
Black	61.6	61.8	63.0	61.0	62.8	61.6	63.3	62.6	64.6	64.4	65.5	64.9	66.3	67.9	67.8	67.8	68.8	68.6	67.3	67.3	67.8
Other race	56.7	53.8	59.4	57.4	55.8	56.6	57.6	56.2	60.6	66.9	66.5	70.7	69.3	71.1	70.7	69.4	69.7	70.5	67.8	71.5	71.9
Diabetes	47.6	46.3	45.7	48.0	47.4	48.3	50.2	51.1	53.2	55.1	55.0	56.1	57.2	59.6	60.1	60.1	60.9	60.7	60.5	61.7	62.1
Hypertension	65.0	63.1	62.5	60.6	62.1	62.2	62.5	61.5	63.0	63.5	63.9	63.6	64.4	65.3	65.9	66.6	67.4	66.0	66.3	66.2	66.4
Glomerulonephritis	69.5	67.1	66.9	65.9	67.8	67.5	66.4	66.8	68.0	68.5	69.2	68.2	70.4	72.3	71.4	72.2	73.5	72.6	73.7	73.6	74.1
Other cause	58.9	61.5	64.5	59.2	60.9	60.1	61.4	60.8	60.0	61.7	63.3	62.2	63.2	63.0	62.9	62.6	62.6	63.2	62.7	62.5	61.9
All	55.8	56.7	57.4	55.3	56.4	56.4	57.4	57.2	58.4	59.7	60.3	60.3	61.5	62.8	63.2	63.6	64.5	64.1	64.1	64.6	64.8

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.
The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, race, or primary diagnosis are excluded.
Includes U.S. & territories; no unknown or foreign states.
†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.4
Five-year Survival Probabilities: Incident ESRD Patients

from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
0-4	78.0	76.7	78.2	75.8	76.3	79.8	77.1	75.0	72.0	76.7	71.6	78.9	84.2	77.3	82.7	77.1	84.7	80.4
5-9	87.4	89.9	85.9	89.3	88.3	89.0	90.2	94.9	93.8	93.0	89.7	95.0	93.4	88.4	94.3	94.8	91.6	93.8
10-14	88.2	84.3	91.0	91.2	91.0	90.6	91.5	95.2	90.6	88.0	89.1	91.0	87.7	88.4	91.7	94.1	93.1	92.3
15-19	89.6	86.7	87.6	88.8	85.9	84.8	87.4	87.0	87.1	89.0	89.3	87.9	90.6	89.8	90.4	90.7	87.6	89.1
20-29	77.0	75.5	77.8	75.3	75.6	75.5	78.5	76.0	78.5	77.7	78.6	78.6	79.0	80.2	81.1	79.3	81.7	82.9
30-39	64.2	65.6	63.7	64.8	64.5	63.8	66.2	63.0	67.0	67.7	67.5	66.2	67.0	68.4	67.8	69.1	69.6	70.4
40-49	55.1	54.7	55.0	53.0	56.4	55.7	56.5	57.4	58.2	56.5	57.7	56.8	58.6	59.4	59.0	60.5	58.7	59.9
50-59	41.2	42.1	41.0	39.8	39.4	38.6	41.0	41.9	41.0	41.5	41.5	43.1	42.9	44.9	45.1	45.1	44.6	45.9
60-64	30.7	31.0	28.9	28.9	27.2	27.6	29.0	28.2	30.1	29.7	30.2	30.3	31.3	32.5	33.0	32.8	33.9	35.2
65-69	23.3	24.6	24.0	20.8	22.4	22.6	22.2	23.3	23.2	23.5	23.5	22.7	24.5	24.9	25.7	25.6	26.6	26.0
70-79	15.8	15.9	16.9	13.7	15.4	15.7	15.1	15.6	16.1	15.8	16.0	16.8	16.7	17.4	18.0	17.2		
80+	8.9	7.7	7.3	6.4	7.9	8.3	7.7	7.9	6.9	9.0	8.8	7.6	7.6	8.0	8.2	8.9	9.0	8.1
Male	43.5	43.6	43.1	38.9	39.5	38.2	39.1	38.3	38.4	38.6	37.9	37.0	36.9	38.3	37.3	38.0	37.0	35.8
Female	43.7	44.6	42.7	38.6	39.5	38.8	38.7	37.4	37.7	36.4	35.8	35.0	35.5	35.3	35.4	34.7	34.2	33.8
White	43.9	43.5	42.0	37.6	38.2	37.5	37.5	36.0	35.3	34.8	33.9	32.9	32.8	33.1	32.6	32.3	31.6	30.5
Black	43.2	45.8	44.8	41.1	42.8	40.9	42.4	42.0	44.0	42.9	43.2	42.1	43.0	43.9	43.4	44.5	43.7	43.5
Other race	41.7	38.7	46.2	41.7	36.0	37.2	37.6	39.7	41.1	44.4	41.9	44.3	44.1	45.4	44.8	40.8	40.8	40.8
†Hispanic																	40.6	40.2
†Non-Hispanic																	35.1	34.3
Diabetes	30.2	27.9	26.3	26.8	26.6	26.7	28.6	27.8	28.8	28.4	27.5	27.7	28.5	29.4	29.6	28.8	28.7	28.5
Hypertension	46.7	41.6	39.2	36.7	36.7	35.6	35.2	33.7	34.8	33.6	34.2	32.3	32.9	33.1	32.8	34.2	33.8	32.9
Glomerulonephritis	65.0	60.8	58.6	56.2	56.6	54.6	54.8	54.9	56.5	55.9	55.9	55.2	56.5	57.7	56.5	57.5	56.5	55.6
Other cause	40.7	46.4	48.9	40.1	43.8	43.6	44.6	44.2	42.9	45.0	44.3	44.0	43.3	44.1	43.1	43.6	42.9	42.6
All	43.6	44.1	42.9	38.8	39.5	38.5	38.9	37.9	38.1	37.6	36.9	36.1	36.3	36.9	36.4	36.4	35.7	34.9
ADJUSTED																		
0-19	80.9	76.8	78.9	80.0	77.6	77.6	79.6	81.0	78.5	80.5	79.6	80.9	83.1	80.2	84.3	84.1	82.6	
20-44	60.7	61.7	62.2	61.4	63.4	62.7	65.2	63.2	65.5	66.0	66.6	65.1	66.0	67.1	67.4	67.6	68.2	
45-64	34.3	35.3	35.2	34.5	34.5	34.6	37.1	37.5	38.5	39.1	39.3	40.7	41.6	43.4	44.0	44.7	44.9	
65-74	18.2	19.5	20.0	16.7	18.7	19.0	18.6	20.0	20.3	20.8	21.1	20.5	22.0	22.5	23.0	23.5	24.6	
75+	10.7	10.6	10.6	8.4	10.1	10.8	10.8	10.5	9.9	11.6	10.8	11.2	10.4	11.3	11.1	12.1	12.7	
Male	28.6	28.6	29.1	27.2	28.4	28.4	29.9	30.0	30.7	32.1	31.9	32.1	32.5	34.3	34.2	35.3	35.8	
Female	30.0	31.5	31.4	29.8	31.2	31.4	32.3	32.5	32.9	33.0	33.4	33.6	34.5	34.8	35.6	35.8	36.4	
White	27.9	27.9	28.2	26.5	27.8	28.2	29.0	29.1	29.4	30.6	30.3	30.6	31.3	32.2	32.7	33.2	34.1	
Black	32.6	34.2	33.4	32.0	33.4	32.6	34.6	34.6	36.1	35.6	36.7	36.5	37.3	38.5	38.5	39.8	39.7	
Other race	27.3	27.4	30.2	30.4	27.1	29.8	30.9	33.5	35.2	39.3	37.6	40.7	40.4	42.5	42.4	40.3	41.2	
Diabetes	21.6	19.9	19.5	20.3	20.7	21.2	23.3	23.5	24.6	25.0	24.9	25.8	26.9	28.1	28.8	28.7	29.4	
Hypertension	38.5	35.6	35.1	34.5	34.8	35.1	35.5	35.4	36.3	36.2	37.3	36.3	36.7	37.4	37.6	39.0	39.5	
Glomerulonephritis	44.0	42.0	40.6	40.2	41.2	40.2	41.2	41.5	42.8	43.5	43.5	44.1	45.1	46.4	46.7	47.4	47.8	
Other cause	32.1	35.1	37.3	32.5	35.4	35.4	36.4	36.6	35.9	38.3	37.3	37.8	37.8	38.7	38.4	39.0	39.0	
All	29.2	29.9	30.2	28.5	29.7	29.9	31.0	31.1	31.7	32.5	32.6	32.8	33.5	34.6	34.9	35.5	36.1	

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, race, or primary diagnosis are excluded. Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

**Table I.5
Ten-year Survival Probabilities: Incident ESRD Patients**
from day 91 to ten years + 90 days, by age, gender, race, ethnicity, & primary diagnosis:

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	75.6	68.3	73.6	70.7	71.1	72.3	75.4	73.2	62.7	75.0	66.7	75.2	79.0
5-9	79.3	79.7	77.8	81.0	85.1	81.3	85.7	82.8	90.0	86.0	84.1	90.0	87.9
10-14	78.9	75.9	76.5	82.9	82.5	82.3	84.6	88.9	81.8	78.9	79.9	85.6	82.1
15-19	80.1	78.0	78.8	80.3	77.7	76.1	77.8	77.9	78.3	82.9	82.6	78.7	80.7
20-29	63.1	61.3	64.1	62.6	62.9	63.9	65.0	64.0	66.6	64.5	66.6	64.8	66.3
30-39	46.4	47.0	47.1	48.3	48.1	46.7	49.3	47.2	49.0	49.4	50.7	49.0	51.1
40-49	32.8	31.8	32.9	32.7	35.0	34.9	35.7	35.5	36.1	34.2	35.1	34.7	36.8
50-59	15.7	17.3	17.3	16.0	16.7	17.3	18.3	19.1	17.5	17.9	18.1	19.0	18.9
60-64	7.7	8.0	6.2	8.3	8.2	9.0	8.7	8.3	8.8	8.4	8.2	8.6	9.7
65-69	4.7	5.3	4.2	4.9	5.2	6.2	5.2	4.8	4.9	4.9	5.2	4.8	4.9
70-79	2.5	2.0	2.8	2.0	2.9	2.7	2.3	2.6	2.4	2.0	2.0	1.8	2.1
80+	3.1	2.1	2.6	0.6	1.8	1.2	0.9	1.0	0.5	0.7	0.4	0.6	0.5
Male	24.5	24.5	24.8	22.5	23.0	22.4	22.9	21.7	21.0	20.6	20.7	19.2	19.8
Female	24.4	24.6	23.4	20.9	21.8	21.2	20.6	19.4	19.5	18.1	17.2	17.0	17.1
White	26.3	25.7	25.0	22.5	23.1	22.4	22.2	20.9	19.7	18.6	18.4	17.3	17.3
Black	20.9	22.3	21.9	19.9	21.1	20.6	20.9	20.1	21.4	20.7	20.0	19.5	20.4
Other race	22.5	22.0	27.7	24.1	22.0	22.0	23.8	21.3	23.4	24.1	24.2	24.2	24.4
Diabetes	12.8	11.5	11.5	11.2	11.7	11.9	12.4	11.6	11.4	11.1	10.3	9.7	10.4
Hypertension	24.5	21.0	18.6	17.8	17.7	16.3	16.6	14.8	15.7	14.7	14.7	14.0	14.7
Glomerulonephritis	46.3	40.6	38.8	37.4	38.3	37.7	38.0	37.0	38.4	37.2	37.7	36.5	38.9
Other cause	21.8	26.2	29.3	24.2	27.2	27.6	27.9	27.7	26.4	27.1	27.8	27.4	26.7
All	24.4	24.5	24.2	21.8	22.5	21.8	21.9	20.7	20.3	19.5	19.1	18.2	18.5
ADJUSTED													
0-19	69.1	66.0	66.3	69.5	68.3	67.0	70.4	70.8	68.0	72.8	71.0	72.1	73.0
20-44	42.4	42.2	44.1	44.3	45.9	45.9	47.4	46.0	47.5	47.5	48.6	47.1	48.9
45-64	12.1	13.0	13.2	13.3	14.2	14.8	16.0	16.3	16.1	16.5	16.5	17.3	18.6
65-74	3.1	3.4	3.1	3.3	3.9	4.4	3.9	3.8	3.8	4.1	3.6	4.0	
75+	1.8	1.5	2.0	0.8	1.7	1.5	1.3	1.5	1.3	1.0	0.8	1.0	0.9
Male	12.8	12.8	13.5	13.2	14.0	14.6	15.0	14.9	14.6	15.0	15.4	15.0	15.9
Female	14.0	14.6	14.5	14.1	15.3	15.4	15.5	15.7	15.3	15.4	15.7	16.2	
White	13.4	13.3	13.7	13.5	14.5	14.8	15.0	15.1	14.7	14.9	15.1	15.1	15.8
Black	12.9	13.6	13.4	13.0	13.9	14.3	14.6	14.4	15.1	14.7	14.9	14.8	15.5
Other race	11.6	13.1	15.1	14.6	14.8	15.7	17.2	16.0	17.8	19.0	19.6	20.1	20.6
Diabetes	8.2	7.7	8.0	8.1	8.7	9.2	9.6	9.6	9.5	9.5	9.5	9.3	10.1
Hypertension	18.3	16.9	16.0	16.5	16.6	16.3	16.9	16.4	16.7	16.6	16.7	16.5	17.2
Glomerulonephritis	23.6	21.4	20.8	21.3	22.6	23.0	23.6	23.2	23.7	23.4	23.7	24.2	25.9
Other cause	15.0	16.6	18.3	16.8	18.9	19.5	19.4	19.8	19.1	19.9	20.3	20.6	20.5
All	13.3	13.6	14.0	13.6	14.6	14.9	15.2	15.2	15.1	15.2	15.4	15.3	16.0

Standard Errors

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	6.6	5.9	4.7	4.5	4.6	4.1	3.9	4.2	4.4	3.9	4.6	3.7	3.7
5-9	4.3	4.5	4.2	4.3	3.7	4.1	3.3	3.8	3.3	3.5	3.5	3.0	3.4
10-14	3.2	3.3	3.0	2.8	2.6	2.7	2.6	2.3	2.9	3.2	3.0	2.5	2.7
15-19	2.0	2.0	2.0	2.0	2.1	2.2	2.1	2.0	2.0	1.8	1.8	2.1	1.9
20-29	1.3	1.2	1.2	1.2	1.1	1.1	1.1	1.1	1.0	1.0	1.0	1.0	1.0
30-39	1.1	1.0	1.0	1.0	0.9	0.9	0.9	0.9	0.8	0.8	0.8	0.8	0.7
40-49	1.0	0.9	0.9	0.9	0.9	0.8	0.8	0.8	0.7	0.7	0.7	0.6	0.6
50-59	0.6	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4
60-64	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4
65-69	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.2	0.2
70-79	0.3	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1
80+	0.9	0.7	0.7	0.3	0.4	0.3	0.3	0.2	0.2	0.2	0.1	0.1	0.1
Male	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2
Female	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.2	0.2
White	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2
Black	0.6	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3
Other race	1.7	1.7	1.9	1.6	1.4	1.3	1.3	1.2	1.1	1.2	1.1	1.0	1.0
Diabetes	0.7	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.2
Hypertension	0.8	0.7	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3
Glomerulonephritis	1.0	0.9	0.8	0.8	0.8	0.7	0.7	0.7	0.7	0.7	0.7	0.6	0.6
Other cause	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4
All	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2
ADJUSTED													
0-19	2.4	2.4	2.4	2.2	2.6	2.4	2.3	2.1	2.2	2.0	2.3	2.3	2.2
20-44	0.8	0.8	0.6	0.7	0.6	0.6	0.6	0.6	0.6	0.5	0.5	0.5	0.4
45-64	0.4	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
65-74	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
75+	0.4	0.3	0.4	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1
Male	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Female	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
White	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1
Black	0.4	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2
Other race	0.9	1.1	1.0	0.9	0.9	0.8	0.9	0.7	0.8	0.8	0.8	0.7	0.7
Diabetes	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2
Hypertension	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2
Glomerulonephritis	0.7	0.6	0.5	0.5	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4
Other cause	0.3	0.3	0.4	0.3	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3
All	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.2	0.1	0.1	0.1	0.1

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, race, or primary diagnosis are excluded. Includes U.S. & territories; no unknown or foreign states.

Table I.6
Incident Patient Counts: ESRD Patients Aged 65 & Over

patients aged 65 & over on day 1, by age, gender, race, ethnicity, & primary diagnosis

	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99	2000-01
65-69	4,336	5,853	7,340	9,447	11,937	14,992	17,255	18,765	20,796	21,743	22,197
70-74	3,250	4,959	6,334	8,096	10,143	13,347	16,500	18,868	21,799	23,326	24,099
75-79	1,874	3,008	4,242	5,772	7,696	9,891	12,190	14,355	17,715	21,002	22,495
80-84	680	1,219	1,822	2,639	3,711	5,096	6,605	8,143	10,605	12,764	14,609
85+	209	422	631	911	1,407	2,050	2,719	3,404	4,789	6,608	7,915
Male	5,684	8,299	10,800	14,061	18,140	23,429	28,260	31,990	38,979	44,091	47,201
Female	4,665	7,162	9,569	12,804	16,754	21,947	27,009	31,545	36,725	41,352	44,114
White	7,128	11,230	14,731	19,554	25,632	33,339	40,644	46,247	55,221	62,753	67,627
Black	2,853	3,841	4,992	6,393	8,176	10,592	12,744	14,476	16,847	18,499	19,369
Other race	368	390	646	918	1,086	1,445	1,881	2,812	3,636	4,191	4,319
†Hispanic									6,662	7,486	8,269
†Non-Hispanic									69,042	77,957	83,046
Diabetes	1,325	2,627	4,175	6,391	9,378	13,839	18,155	23,205	31,003	35,843	39,212
Hypertension	2,671	5,173	7,221	9,996	13,630	17,939	21,625	23,072	25,909	29,354	30,957
Glomerulonephritis	1,083	1,841	2,438	2,875	3,366	4,044	4,343	5,063	5,648	5,601	5,129
Cystic kidney	278	403	445	540	568	690	729	909	999	1,044	1,061
Other urologic	391	472	680	786	886	975	947	1,052	1,513	1,614	1,655
Other cause	1,110	1,997	2,499	3,087	3,574	3,930	4,607	5,854	7,084	7,977	8,834
Unknown cause	1,266	1,466	1,815	2,524	3,000	3,648	4,459	4,207	3,391	3,810	4,273
Missing cause	2,225	1,482	1,096	666	492	311	404	173	157	200	194
All	10,349	15,461	20,369	26,865	34,894	45,376	55,269	63,535	75,704	85,443	91,315

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Includes patients from U.S. & territories only.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.7
One-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over

from day 1 to one year, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99	2000-01
65-69	71.1	70.9	69.9	72.1	73.0	73.8	75.1	75.6	75.6	75.2	75.0
70-74	66.4	67.1	64.9	66.1	66.8	68.2	69.9	70.2	70.1	69.9	69.1
75-79	60.9	60.3	61.9	60.8	61.2	63.8	63.4	64.6	64.3	63.3	63.5
80-84	53.8	56.8	55.4	56.1	57.4	57.7	59.0	59.0	58.8	56.6	56.0
85+	49.8	50.9	47.5	49.6	46.9	51.1	51.1	51.8	48.8	47.4	48.1
Male	65.2	63.9	62.9	63.8	64.2	65.9	67.1	67.2	66.6	65.6	65.1
Female	67.5	68.5	66.7	67.4	67.7	68.5	68.7	69.0	68.0	66.2	65.4
White	65.0	63.8	62.6	62.9	63.3	64.6	65.3	65.8	65.2	64.2	63.5
Black	69.0	72.4	70.9	73.4	73.2	74.1	74.8	74.6	73.0	70.6	69.7
Other race	67.7	65.9	65.3	67.4	70.8	75.6	75.7	73.6	72.8	71.2	73.0
†Hispanic									71.3	71.1	70.5
†Non-Hispanic									66.9	65.4	64.7
Diabetes	64.8	60.6	62.7	65.1	66.8	68.3	69.7	69.9	69.3	67.9	67.7
Hypertension	68.4	65.3	64.8	64.7	64.8	65.7	65.8	66.7	66.4	65.1	64.1
Glomerulonephritis	74.2	73.3	73.6	72.4	72.4	72.5	74.9	74.1	74.6	73.5	73.6
Other cause	63.8	66.7	62.5	64.3	64.0	65.8	66.1	65.0	61.1	59.5	58.5
All	66.2	66.0	64.7	65.5	65.9	67.1	67.9	68.1	67.3	65.9	65.2
ADJUSTED											
65-69	68.9	69.3	68.6	71.1	72.4	73.5	75.0	75.7	75.9	75.6	75.4
70-74	64.7	65.8	63.6	65.2	66.2	67.8	69.8	70.2	70.2	70.1	69.6
75-79	59.6	59.0	60.8	59.9	60.5	63.3	63.1	64.3	64.3	63.5	63.8
80-84	52.5	55.8	54.3	55.3	56.7	57.1	58.5	58.6	58.6	56.7	56.2
85+	48.9	50.0	46.4	48.7	45.9	50.4	50.5	51.2	48.3	47.1	48.0
Male	60.8	60.4	60.0	61.4	62.3	64.4	66.1	66.6	66.7	66.3	66.3
Female	62.6	64.7	63.4	64.7	65.6	66.8	67.6	68.2	67.9	66.7	66.4
White	60.5	59.9	59.3	60.1	61.2	63.0	64.3	65.1	65.3	64.9	64.7
Black	65.7	69.8	68.5	71.2	71.2	72.4	73.4	73.5	72.2	70.1	69.5
Other race	63.5	63.2	62.7	65.2	69.7	74.3	74.7	73.1	72.8	71.6	73.7
Diabetes	58.7	55.4	57.8	60.5	62.8	64.7	66.6	67.0	67.1	66.2	66.5
Hypertension	65.7	63.5	63.5	63.9	64.5	65.9	66.4	67.6	67.9	67.3	66.8
Glomerulonephritis	71.7	71.3	72.1	71.2	71.6	72.3	74.7	74.5	75.2	74.6	74.8
Other cause	61.5	65.1	61.4	63.6	63.5	65.4	66.0	65.3	62.2	61.2	60.5
All	61.7	62.4	61.6	63.0	63.9	65.6	66.8	67.4	67.3	66.5	66.3

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Standard Errors

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99	2000-01
65-69	0.7	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3	0.3
70-74	0.8	0.7	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3
75-79	1.1	0.9	0.7	0.6	0.6	0.5	0.4	0.4	0.4	0.3	0.3
80-84	1.9	1.4	1.2	1.0	0.8	0.7	0.6	0.5	0.5	0.4	0.4
85+	3.4	2.4	2.0	1.7	1.3	1.1	1.0	0.9	0.7	0.6	0.6
Male	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.2
Female	0.7	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.2
White	0.6	0.5	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2
Black	0.9	0.7	0.6	0.6	0.5	0.4	0.4	0.4	0.3	0.3	0.3
Other race	2.4	2.4	1.9	1.5	1.4	1.1	1.0	0.8	0.7	0.7	0.7
†Hispanic									0.6	0.5	0.5
†Non-Hispanic									0.2	0.2	0.2
Diabetes	1.3	1.0	0.7	0.6	0.5	0.4	0.3	0.3	0.3	0.2	0.2
Hypertension	0.9	0.7	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.3	0.3
Glomerulonephritis	1.3	1.0	0.9	0.8	0.8	0.7	0.7	0.6	0.6	0.6	0.6
Other cause	0.7	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4
All	0.5	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2
ADJUSTED											
65-69	0.7	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3	0.3
70-74	0.9	0.7	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3
75-79	1.2	0.9	0.7	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3
80-84	1.9	1.4	1.2	1.0	0.9	0.7	0.6	0.6	0.4	0.4	0.4
85+	3.3	2.7	2.0	1.7	1.4	1.1	1.0	0.9	0.8	0.6	0.6
Male	0.7	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.2
Female	0.8	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.2
White	0.6	0.5	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2
Black	0.9	0.8	0.7	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3
Other race	2.5	2.5	1.8	1.6	1.3	1.2	1.0	0.9	0.8	0.7	0.6
Diabetes	1.4	1.0	0.8	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.3
Hypertension	0.9	0.7	0.6	0.5	0.4	0.3	0.3	0.3	0.3	0.3	0.3
Glomerulonephritis	1.4	1.0	1.0	0.8	0.8	0.7	0.7	0.6	0.6	0.5	0.6
Other cause	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4
All	0.5	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2

Table I.8
Two-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over

from day 1 to two years, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99
65-69	53.3	52.2	51.7	53.6	55.2	56.0	58.1	58.6	59.2	58.7
70-74	47.4	47.7	46.5	47.1	48.0	49.1	50.9	51.8	51.8	52.4
75-79	41.5	39.5	41.1	40.6	41.7	43.6	44.4	45.2	45.1	44.8
80-84	33.4	34.6	35.7	33.5	35.7	36.7	38.0	39.0	38.3	36.8
85+	30.6	28.9	27.3	27.4	28.5	28.2	29.1	30.1	29.0	28.1
Male	46.1	43.7	43.2	43.9	45.2	46.6	47.9	48.5	48.2	47.8
Female	49.3	49.3	48.5	48.2	48.9	49.2	50.4	50.5	49.8	48.1
White	46.3	43.9	43.4	43.1	44.1	44.7	46.0	46.5	46.2	45.7
Black	50.8	53.4	52.5	54.9	55.3	56.3	57.7	57.7	56.4	54.0
Other race	45.1	44.9	45.7	45.9	51.5	58.6	58.8	56.5	55.9	54.3
†Hispanic									52.9	53.6
†Non-Hispanic									48.6	47.4
Diabetes	41.6	38.2	41.3	42.4	45.0	46.7	49.3	49.7	49.5	48.8
Hypertension	49.7	45.4	46.3	45.3	46.8	46.8	47.4	48.7	48.5	47.2
Glomerulonephritis	54.6	54.9	54.6	53.5	54.5	55.3	57.4	56.9	57.2	56.9
Other cause	46.5	48.0	44.5	47.0	46.4	48.1	48.9	47.6	44.9	43.7
All	47.5	46.3	45.7	46.0	47.0	47.8	49.1	49.5	48.9	47.9
ADJUSTED										
65-69	50.0	49.7	49.7	52.0	54.3	55.5	57.9	58.7	59.7	59.3
70-74	44.9	45.7	44.7	45.8	47.1	48.6	50.6	51.7	52.0	52.9
75-79	39.6	37.7	39.6	39.3	40.7	42.9	44.0	44.8	45.1	45.1
80-84	31.7	33.3	34.4	32.4	34.9	35.8	37.3	38.5	38.1	36.8
85+	29.7	27.7	25.9	26.4	27.4	27.4	28.4	29.3	28.5	27.8
Male	40.6	39.3	39.6	40.9	42.8	44.7	46.5	47.7	48.2	48.6
Female	43.0	44.3	44.4	44.6	46.2	47.1	48.8	49.5	49.6	48.7
White	40.5	39.0	39.3	39.7	41.5	42.7	44.6	45.7	46.3	46.6
Black	46.4	49.8	49.2	51.8	52.6	54.0	55.7	56.1	55.4	53.3
Other race	39.4	41.1	42.6	42.9	50.2	56.8	57.4	55.8	56.0	55.0
Diabetes	34.8	32.6	36.0	37.0	40.3	42.3	45.2	46.1	46.6	46.6
Hypertension	46.3	43.1	44.7	44.2	46.5	47.0	48.1	49.8	50.4	49.9
Glomerulonephritis	51.3	52.3	52.6	52.0	53.5	55.1	57.2	57.4	58.0	58.5
Other cause	43.7	46.0	43.2	46.0	45.8	47.6	48.8	48.0	46.2	45.7
All	41.8	41.6	41.9	42.7	44.4	45.8	47.7	48.6	48.9	48.7

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule. The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, race, or primary diagnosis are excluded. Includes U.S. & territories; no unknown or foreign states. †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Standard Errors

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99
65-69	0.8	0.7	0.6	0.5	0.5	0.4	0.4	0.4	0.3	0.3
70-74	0.9	0.7	0.6	0.6	0.5	0.4	0.4	0.4	0.3	0.3
75-79	1.1	0.9	0.8	0.6	0.6	0.5	0.4	0.4	0.4	0.3
80-84	1.8	1.4	1.1	0.9	0.8	0.7	0.6	0.5	0.5	0.4
85+	3.2	2.2	1.8	1.5	1.2	1.0	0.9	0.8	0.7	0.6
Male	0.7	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3	0.2
Female	0.7	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.3	0.2
White	0.6	0.5	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.2
Black	0.9	0.8	0.7	0.6	0.5	0.5	0.4	0.4	0.4	0.4
Other race	2.6	2.5	2.0	1.6	1.5	1.3	1.1	0.9	0.8	0.8
†Hispanic									0.6	0.6
†Non-Hispanic									0.2	0.2
Diabetes	1.4	0.9	0.8	0.6	0.5	0.4	0.4	0.3	0.3	0.3
Hypertension	1.0	0.7	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.3
Glomerulonephritis	1.5	1.2	1.0	0.9	0.9	0.8	0.7	0.7	0.7	0.7
Other cause	0.7	0.7	0.6	0.6	0.5	0.5	0.5	0.5	0.4	0.4
All	0.5	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2
ADJUSTED										
65-69	0.8	0.7	0.6	0.5	0.5	0.4	0.4	0.4	0.3	0.3
70-74	0.9	0.7	0.6	0.6	0.5	0.4	0.4	0.3	0.3	0.3
75-79	1.2	0.9	0.7	0.6	0.6	0.5	0.5	0.4	0.3	0.3
80-84	1.9	1.4	1.1	0.9	0.8	0.7	0.6	0.5	0.5	0.4
85+	3.0	2.2	1.8	1.5	1.2	1.1	1.0	0.8	0.7	0.5
Male	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.2
Female	0.8	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.3	0.2
White	0.6	0.5	0.4	0.3	0.3	0.3	0.3	0.2	0.2	0.2
Black	0.9	0.8	0.7	0.7	0.6	0.5	0.4	0.4	0.4	0.4
Other race	2.6	2.5	1.9	1.6	1.5	1.3	1.1	0.9	0.9	0.7
Diabetes	1.4	0.9	0.8	0.6	0.5	0.4	0.4	0.3	0.3	0.3
Hypertension	1.0	0.7	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.3
Glomerulonephritis	1.6	1.1	1.0	0.9	0.8	0.8	0.7	0.7	0.6	0.6
Other cause	0.7	0.7	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4
All	0.5	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2

Table I.9
Five-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over

from day 1 to five years, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97
65-69	23.3	21.5	21.9	22.4	23.1	23.0	24.5	25.5	26.0
70-74	16.7	16.6	16.9	16.7	17.5	17.6	18.8	19.1	19.4
75-79	12.8	11.2	11.9	12.7	12.5	12.7	12.7	13.5	14.3
80-84	6.8	6.9	8.4	7.8	8.6	9.0	8.6	9.1	9.4
85+	9.6	5.5	5.1	5.5	5.5	5.2	5.4	5.7	5.3
Male	16.4	14.3	14.6	15.1	16.0	16.0	16.2	16.9	17.2
Female	19.9	18.7	18.7	18.2	17.8	17.6	18.5	18.6	18.3
White	16.9	15.2	15.0	14.7	15.0	14.5	15.0	15.3	15.6
Black	20.7	19.8	21.1	22.2	22.6	23.4	23.9	24.6	23.5
Other race	16.8	15.6	15.8	16.6	19.4	22.6	24.4	22.5	23.8
†Hispanic									19.8
†Non-Hispanic									17.5
Diabetes	11.8	9.7	11.9	12.9	13.0	13.9	15.1	16.0	15.9
Hypertension	19.3	16.6	16.5	16.3	16.7	16.6	16.6	17.5	17.8
Glomerulonephritis	22.0	22.5	21.7	21.9	22.5	23.0	24.5	24.4	25.1
Other cause	18.0	17.1	17.6	17.9	19.1	18.9	19.6	18.7	18.5
All	17.9	16.3	16.5	16.6	16.9	16.8	17.3	17.7	17.7
ADJUSTED									
65-69	20.1	19.0	19.9	20.7	22.1	22.4	24.1	25.5	26.5
70-74	14.8	14.7	15.4	15.6	16.6	17.0	18.4	19.0	19.6
75-79	11.2	10.1	10.8	11.6	11.8	12.2	12.4	13.2	14.3
80-84	6.1	6.2	7.6	7.2	8.1	8.5	8.3	8.8	9.3
85+	9.0	5.0	4.5	5.2	5.0	5.0	5.1	5.4	5.2
Male	12.4	11.3	12.2	13.0	14.2	14.6	15.1	16.2	17.2
Female	14.8	14.7	15.3	15.3	15.6	15.9	17.1	17.6	18.1
White	12.5	11.5	12.0	12.2	13.0	12.9	13.8	14.6	15.6
Black	16.9	16.5	18.3	19.5	20.1	21.3	21.8	22.9	22.4
Other race	12.7	12.9	13.8	14.2	18.4	21.0	22.9	21.9	23.7
Diabetes	8.2	7.1	9.1	9.9	10.3	11.1	12.4	13.5	14.0
Hypertension	16.5	14.8	15.2	15.5	16.4	16.6	17.1	18.3	19.3
Glomerulonephritis	19.5	20.6	20.3	20.8	21.9	22.9	24.5	24.8	26.0
Other cause	16.0	15.7	16.7	17.3	18.7	18.5	19.5	19.1	19.5
All	13.6	12.9	13.7	14.1	14.9	15.2	16.1	16.9	17.6

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Standard Errors

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97
65-69	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3
70-74	0.7	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3
75-79	0.8	0.6	0.5	0.4	0.4	0.3	0.3	0.3	0.3
80-84	1.0	0.7	0.6	0.5	0.5	0.4	0.3	0.3	0.3
85+	2.0	1.1	0.9	0.8	0.6	0.5	0.4	0.4	0.3
Male	0.5	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2
Female	0.6	0.5	0.4	0.3	0.3	0.3	0.2	0.2	0.2
White	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2
Black	0.8	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.3
Other race	1.9	1.8	1.4	1.2	1.2	1.1	1.0	0.8	0.7
†Hispanic									0.5
†Non-Hispanic									0.1
Diabetes	0.9	0.6	0.5	0.4	0.3	0.3	0.3	0.2	0.2
Hypertension	0.8	0.5	0.4	0.4	0.3	0.3	0.3	0.2	0.2
Glomerulonephritis	1.3	1.0	0.8	0.8	0.7	0.7	0.7	0.6	0.6
Other cause	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3
All	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.1
ADJUSTED									
65-69	0.6	0.5	0.5	0.4	0.4	0.3	0.3	0.3	0.3
70-74	0.6	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3
75-79	0.8	0.6	0.5	0.4	0.3	0.3	0.3	0.3	0.3
80-84	0.9	0.7	0.6	0.5	0.5	0.4	0.3	0.3	0.3
85+	2.0	1.0	0.8	0.7	0.6	0.5	0.5	0.4	0.3
Male	0.4	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2
Female	0.5	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.2
White	0.4	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2
Black	0.7	0.6	0.6	0.5	0.4	0.4	0.3	0.3	0.3
Other race	1.6	1.6	1.3	1.1	1.2	1.0	1.0	0.7	0.7
Diabetes	0.7	0.5	0.4	0.3	0.3	0.3	0.2	0.2	0.2
Hypertension	0.7	0.5	0.4	0.3	0.3	0.3	0.3	0.3	0.2
Glomerulonephritis	1.2	0.9	0.8	0.7	0.7	0.6	0.7	0.6	0.6
Other cause	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.3
All	0.3	0.3	0.2	0.2	0.2	0.2	0.1	0.1	0.1

Table I.10
Ten-year Survival Probabilities: Incident ESRD Patients Aged 65 & Over

from day 1 to ten years, by age, gender, & race, ethnicity, & primary diagnosis

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93
65-69	5.0	4.5	5.7	5.0	4.8	5.0	5.2
70-74	2.6	2.7	3.1	2.9	2.6	2.4	2.7
75-79	1.5	1.4	1.7	1.8	1.4	1.2	1.4
80-84	1.0	1.0	1.1	0.8	0.6	0.6	0.6
85+	5.7	1.9	1.7	1.1	0.4	0.4	0.4
Male	3.0	2.4	3.2	3.1	2.5	2.5	2.6
Female	3.9	3.6	3.9	3.2	3.1	2.9	3.0
White	3.3	2.7	3.3	2.9	2.4	2.2	2.4
Black	3.8	3.8	4.4	3.9	4.1	4.1	4.1
Other race	2.4	4.4	2.8	4.4	3.5	4.8	4.8
Diabetes	1.7	1.6	2.1	1.9	1.6	1.6	1.8
Hypertension	3.6	2.8	3.1	2.7	2.4	2.3	2.6
Glomerulonephritis	4.1	4.2	5.1	5.1	4.7	4.9	4.9
Other cause	3.6	3.4	4.4	4.1	4.0	4.1	4.2
All	3.4	3.0	3.6	3.2	2.8	2.7	2.8
ADJUSTED							
65-69	3.8	3.6	4.8	4.3	4.4	4.7	5.0
70-74	2.1	2.1	2.6	2.7	2.3	2.3	2.6
75-79	1.2	1.2	1.5	1.6	1.3	1.1	1.3
80-84	0.9	0.9	1.0	0.6	0.6	0.5	0.6
85+	5.2	1.7	1.5	1.0	0.3	0.4	0.4
Male	1.9	1.7	2.4	2.4	2.0	2.1	2.3
Female	2.4	2.4	2.8	2.4	2.4	2.4	2.7
White	1.9	1.6	2.2	2.0	1.8	1.7	2.0
Black	2.7	2.7	3.4	3.1	3.3	3.3	3.4
Other race	1.6	3.3	2.4	3.4	3.2	4.0	4.2
Diabetes	1.0	1.2	1.5	1.4	1.1	1.1	1.3
Hypertension	2.9	2.3	2.7	2.5	2.4	2.3	2.7
Glomerulonephritis	3.4	3.8	4.6	4.8	4.4	4.9	4.9
Other cause	3.1	3.0	4.1	3.9	3.9	3.9	4.2
All	2.1	2.0	2.6	2.4	2.2	2.2	2.5

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Includes U.S. & territories; no unknown or foreign states.

**Table I.11
Incident Patient Counts: Dialysis Patients**

dialysis patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	27	45	61	77	79	95	101	86	93	95	81	114	100	99	88	97	99	91	82	80	106	95
5-9	63	53	71	65	68	55	80	73	57	64	77	59	53	61	89	67	66	56	62	70	65	66
10-14	133	137	164	144	154	140	126	120	124	108	127	139	147	152	156	152	163	147	139	134	152	141
15-19	343	364	335	345	315	318	312	327	357	389	343	319	380	352	320	356	360	294	336	333	316	328
20-29	1,221	1,376	1,548	1,487	1,621	1,662	1,706	1,700	1,789	1,902	1,931	1,997	2,082	2,040	1,995	1,907	1,949	1,799	1,841	1,727	1,796	1,806
30-39	1,883	2,094	2,342	2,419	2,594	2,741	2,980	3,021	3,337	3,671	3,795	3,958	4,240	4,200	4,349	4,179	4,194	3,988	3,930	4,083	3,926	3,943
40-49	2,158	2,447	2,534	2,846	2,956	3,217	3,432	3,815	4,148	4,776	5,073	5,719	6,142	6,433	6,636	6,949	7,302	7,082	7,632	7,594	7,815	7,746
50-59	3,372	3,990	4,257	4,367	4,625	4,912	5,156	5,496	6,158	6,677	7,065	7,639	8,446	8,740	9,700	9,698	10,035	10,741	11,495	12,217	12,521	13,112
60-64	1,907	2,183	2,458	2,869	3,161	3,491	3,615	4,047	4,424	4,782	5,157	5,698	5,970	6,171	6,404	6,625	6,886	7,045	7,412	7,544	7,805	8,035
65-69	1,944	1,989	2,276	3,029	3,090	3,495	4,018	4,584	5,093	5,879	6,528	7,246	7,814	8,100	8,664	8,644	9,437	9,697	9,953	10,014	10,023	10,241
70-79	2,150	2,338	2,889	4,120	4,262	4,965	5,717	6,551	7,203	8,529	9,533	11,202	12,494	13,085	14,624	15,024	16,931	18,094	19,067	20,183	20,521	20,601
80+	356	388	536	841	903	1,126	1,369	1,604	1,936	2,399	2,775	3,241	3,801	4,109	4,645	5,027	6,030	6,824	7,498	8,436	9,083	9,484
Male	8,639	9,558	10,648	12,343	13,125	14,192	15,562	16,938	18,620	21,180	22,872	25,307	27,374	28,632	30,586	31,071	34,011	35,165	37,114	38,957	39,904	40,823
Female	6,918	7,846	8,823	10,266	10,703	12,025	13,050	14,486	16,099	18,091	19,613	22,024	24,295	24,910	27,084	27,654	29,441	30,693	32,333	33,458	34,225	34,775
White	9,834	11,263	13,159	14,839	15,763	17,360	19,027	20,708	22,731	25,726	28,007	31,138	33,807	34,846	37,506	37,477	40,770	42,769	44,796	47,409	48,880	49,574
Black	5,167	5,562	5,771	7,044	7,234	7,909	8,522	9,546	10,625	12,211	12,930	14,447	15,895	16,535	17,622	17,954	19,228	19,619	20,803	20,994	21,148	21,787
Other race	556	579	541	726	831	948	1,063	1,170	1,363	1,334	1,548	1,746	1,967	2,161	2,542	3,294	3,454	3,470	3,848	4,012	4,101	4,237
†Hispanic																	7,070	7,101	7,520	8,048	8,545	8,758
†Non-Hispanic																	56,382	58,757	61,927	64,367	65,584	66,840
Diabetes	2,340	3,414	4,524	5,298	6,402	7,389	8,477	9,572	10,919	13,247	15,028	17,215	19,205	20,122	22,432	24,957	28,148	29,805	31,540	33,236	34,524	35,373
Hypertension	2,678	3,872	4,920	5,489	6,083	6,976	7,611	8,696	9,928	11,503	12,652	13,956	15,478	15,949	17,069	15,726	17,090	18,204	18,866	19,907	20,128	20,725
Glomerulonephritis	2,201	2,820	3,337	3,593	3,868	4,040	4,075	4,389	4,662	4,915	5,200	5,530	5,695	5,790	6,167	6,366	6,719	6,297	6,658	6,466	6,192	6,072
Cystic kidney	673	810	940	949	953	999	1,059	1,091	1,101	1,085	1,172	1,265	1,293	1,351	1,358	1,490	1,432	1,458	1,499	1,589	1,563	1,568
Other urologic	366	463	470	537	545	676	665	646	699	725	732	843	887	755	751	962	1,224	1,135	1,160	1,293	1,252	1,257
Other cause	1,700	2,282	2,902	3,102	3,211	3,468	3,688	3,815	3,916	4,436	4,309	4,669	5,053	5,079	5,463	6,490	6,388	6,534	7,072	7,201	7,506	7,576
Unknown cause	1,529	1,768	1,656	1,795	1,930	2,019	2,376	2,692	2,831	2,922	3,090	3,590	3,868	4,150	4,316	2,632	2,377	2,364	2,584	2,622	2,840	2,929
Missing cause	4,070	1,975	722	1,846	836	650	661	523	663	438	302	263	190	346	114	102	74	61	68	101	124	98
All	15,557	17,404	19,471	22,609	23,828	26,217	28,612	31,424	34,719	39,271	42,485	47,331	51,669	53,542	57,670	58,725	63,452	65,858	69,447	72,415	74,129	75,598

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.12
One-year Survival Probabilities: Incident Dialysis Patients

censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	95.5	91.4	87.7	88.5	85.3	85.5	92.7	93.7	78.9	82.7	78.5	82.4	89.2	85.3	89.2	82.6	91.1	85.1	87.3	87.4	84.4	86.4
5-9	91.9	95.6	95.5	98.0	88.7	88.7	100.0	100.0	100.0	100.0	94.3	94.8	94.4	96.1	100.0	98.4	93.7	95.8	100.0	98.5	98.1	95.1
10-14	97.2	98.4	97.4	98.1	96.6	97.4	98.8	98.8	95.3	95.3	95.3	97.4	94.0	93.4	99.1	97.2	97.4	96.1	97.1	95.9	95.9	97.6
15-19	96.0	94.4	94.6	94.8	96.4	93.0	93.9	94.9	96.9	98.2	96.5	95.7	96.8	95.8	95.0	97.7	96.3	97.9	95.4	98.2	96.3	97.5
20-29	90.1	92.4	91.9	92.2	92.1	90.7	93.0	90.4	91.7	91.6	91.9	91.5	92.9	92.3	93.0	92.2	94.3	95.7	95.3	95.1	93.2	94.6
30-39	88.5	88.9	88.1	89.2	87.0	87.6	88.0	87.4	88.5	88.2	89.2	88.4	89.4	88.8	89.4	89.4	90.1	91.4	90.7	91.2	91.4	91.3
40-49	87.7	87.0	86.1	87.3	86.7	86.4	86.5	86.9	87.7	87.7	88.6	86.9	87.7	88.8	88.9	89.1	89.6	89.9	88.9	89.6	89.8	89.4
50-59	83.0	83.3	83.9	81.2	81.7	81.8	82.0	82.6	83.1	82.5	83.9	83.6	84.8	84.8	85.9	85.9	85.3	85.6	85.4	85.9	85.4	86.1
60-64	77.8	77.1	77.4	76.9	75.4	75.9	76.6	75.8	76.2	77.2	78.1	78.7	79.2	80.9	80.8	80.2	81.6	81.8	80.2	81.2	81.0	81.6
65-69	73.0	73.5	73.6	72.0	72.7	71.0	73.0	73.1	73.2	73.7	75.3	74.9	75.3	77.1	76.1	77.0	77.7	76.8	76.1	76.3	76.7	76.7
70-79	66.8	68.0	68.2	65.2	66.2	66.6	66.2	65.4	66.0	67.2	68.3	68.1	68.3	69.8	70.1	70.2	70.8	69.8	69.8	69.4	69.4	69.6
80+	58.7	54.1	62.9	54.9	56.7	57.9	58.9	55.3	55.7	57.6	59.4	59.2	58.4	61.0	61.0	60.4	60.3	59.4	57.5	58.2	57.8	57.8
Male	79.8	80.5	79.9	77.2	77.2	76.6	76.5	76.3	76.1	76.9	77.8	77.2	77.5	78.9	78.6	78.4	78.7	78.1	77.4	77.7	77.3	77.6
Female	80.7	80.5	80.7	78.2	78.2	77.6	78.4	76.7	78.0	77.4	78.2	77.4	77.8	78.4	78.5	78.5	78.3	77.5	76.7	76.4	76.3	76.3
White	79.1	79.2	78.6	75.6	75.1	74.8	75.0	73.8	74.2	74.4	75.2	74.4	74.6	75.8	75.9	75.8	75.8	74.7	74.3	74.4	74.2	74.1
Black	82.3	83.3	83.7	81.6	83.0	81.6	82.2	82.3	82.4	82.1	83.3	82.6	83.3	83.7	83.3	83.0	83.6	83.6	82.2	82.2	81.8	82.3
Other race	80.1	78.8	83.2	79.6	77.8	79.4	79.4	74.7	79.2	82.8	83.5	84.7	83.3	85.0	84.5	82.9	82.4	82.5	80.6	82.0	82.6	84.3
†Hispanic																	82.5	82.0	82.2	82.0	82.8	82.5
†Non-Hispanic																	78.0	77.3	76.4	76.5	76.0	76.3
Diabetes	73.9	72.8	72.2	71.9	72.5	72.0	73.6	73.6	74.9	75.6	75.9	76.1	76.4	78.3	78.4	78.0	78.1	77.6	76.6	77.3	77.2	77.5
Hypertension	82.8	81.2	79.2	77.5	76.9	77.6	76.9	75.3	75.7	75.9	77.0	76.0	76.2	76.9	76.8	77.5	77.6	76.3	75.7	75.5	75.5	75.4
Glomerulonephritis	90.4	88.1	87.1	85.9	86.3	86.0	84.6	84.7	85.1	85.3	85.4	84.4	86.3	87.2	86.2	86.5	87.0	86.5	86.8	86.5	86.4	86.5
Other cause	78.5	80.9	83.2	78.0	78.4	76.9	78.2	77.0	76.9	76.8	78.7	77.4	77.7	77.7	77.7	76.5	76.1	76.3	75.1	74.5	73.6	74.1
All	80.2	80.5	80.3	77.6	77.7	77.1	77.4	76.5	77.0	77.2	78.0	77.3	77.7	78.7	78.6	78.5	78.5	77.8	77.0	77.1	76.8	77.0
ADJUSTED																						
0-19	92.3	91.0	90.2	90.5	88.5	86.4	91.4	92.5	88.8	92.0	88.4	88.2	90.4	88.6	92.1	91.2	92.0	91.6	91.0	93.3	89.7	91.8
20-44	87.1	88.4	88.0	88.4	87.4	87.2	87.9	87.3	88.5	87.9	89.0	87.9	88.8	88.4	89.5	89.2	90.4	91.1	90.4	90.9	90.9	90.9
45-64	79.8	79.8	80.5	79.3	79.1	79.4	80.1	80.0	80.6	81.4	82.5	82.4	83.4	84.4	84.8	84.9	85.2	85.7	84.8	85.6	85.3	85.7
65-74	69.6	70.2	71.8	68.7	69.7	68.7	70.0	70.1	70.7	71.4	73.0	72.6	73.2	75.2	74.3	75.2	75.9	75.1	74.8	75.1	75.1	75.1
75+	60.4	61.6	61.8	58.4	60.6	61.8	61.9	59.1	59.8	62.0	63.1	63.1	62.6	64.0	64.9	64.5	64.8	63.9	63.0	63.2	63.0	63.2
Male	73.4	74.3	74.4	72.3	72.6	72.6	73.0	73.0	73.0	74.4	75.7	75.5	76.0	77.7	77.7	77.7	78.6	78.4	77.9	78.5	78.3	78.6
Female	74.6	74.7	75.9	74.1	74.5	74.3	75.8	74.5	76.0	76.1	77.3	76.8	77.5	78.2	78.6	79.0	79.2	78.8	78.1	78.1	78.2	78.3
White	72.3	72.7	73.0	70.8	70.8	71.1	71.9	71.2	72.1	73.1	74.2	73.8	74.5	75.9	76.3	76.6	77.1	76.6	76.4	76.8	76.7	76.7
Black	77.8	78.2	78.9	77.7	79.0	77.7	78.7	78.9	79.0	78.8	80.5	80.1	80.8	81.3	81.2	81.0	81.9	82.1	80.7	80.7	80.5	81.1
Other race	73.8	73.4	77.4	75.3	73.2	75.9	77.0	72.1	77.2	81.1	82.3	83.7	82.1	84.2	83.7	82.8	82.7	83.1	81.2	83.0	83.3	84.8
Diabetes	68.3	67.2	67.3	67.2	68.2	67.9	70.2	70.3	72.1	73.3	73.9	74.4	74.9	77.0	77.3	77.0	77.5	77.3	76.5	77.3	77.4	77.7
Hypertension	79.3	78.4	77.2	76.2	75.9	77.3	77.2	76.0	76.5	77.2	78.5	77.9	78.1	79.0	79.1	79.8	80.3	79.4	79.2	79.1	79.2	79.1
Glomerulonephritis	85.7	83.2	82.4	81.6	82.2	82.6	81.1	81.4	81.5	82.4	82.6	81.7	83.8	84.8	84.2	84.4	85.4	85.1	85.0	85.2	85.0	84.8
Other cause	75.1	76.9	79.7	75.9	75.9	74.4	76.0	75.0	74.8	75.0	77.0	75.9	76.4	76.3	76.7	75.7	75.5	76.1	74.9	74.8	73.9	74.4
All	74.0	74.5	75.1	73.2	73.5	73.4	74.3	73.7	74.4	75.2	76.5	76.1	76.7	77.9	78.1	78.3	78.9	78.6	78.0	78.3	78.2	78.5

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Standard Errors

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	4.3	4.7	4.7	4.2	4.6	4.1	2.9	3.1	4.4	4.4	4.9	3.9	3.4	3.9	3.6	4.1	3.2	4.2	4.0	4.2	3.7	3.7
5-9	4.4	3.0	3.2	1.9	4.9	4.7	0.0	0.0	0.0	0.0	3.2	3.6	3.9	2.7	0.0	1.6	3.5	2.9	0.0	1.5	1.8	2.8
10-14	1.6	1.1	1.5	1.3	1.7	1.5	1.2	1.2	2.3	2.3	2.1	1.5	2.2	2.3	0.8	1.6	1.5	1.9	1.7	2.0	1.8	1.3
15-19	1.2	1.3	1.5	1.4	1.2	1.8	1.6	1.4	1.1	0.8	1.1	1.2	1.0	1.2	1.4	0.9	1.1	0.9	1.3	0.8	1.2	1.0
20-29	1.0	0.8	0.8	0.8	0.8	0.8	0.7	0.8	0.7	0.7	0.7	0.7	0.6	0.6	0.6	0.7	0.6	0.5	0.5	0.5	0.6	0.6
30-39	0.8	0.8	0.7	0.7	0.7	0.7	0.7	0.7	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
40-49	0.7	0.7	0.7	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.4
50-59	0.7	0.6	0.6	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3
60-64	1.0	0.9	0.8	0.8	0.8	0.7	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4
65-69	1.0	1.0	0.9	0.8	0.8	0.8	0.7	0.7	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4
70-79	1.0	1.0	0.9	0.7	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
80+	2.6	2.5	2.1	1.7	1.6	1.5	1.3	1.2	1.1	1.0	0.9	0.9	0.8	0.8	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5
Male	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Female	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2
White	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Black	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Other race	1.8	1.8	1.7	1.5	1.5	1.4	1.3	1.3	1.1	1.1	1.0	0.9	0.9	0.8	0.7	0.7	0.6	0.6	0.6	0.6	0.6	0.6
†Hispanic		0.5	0.5	0.4	0.4	0.4	0.4
†Non-Hispanic		0.2	0.2	0.2	0.2	0.2	0.2
Diabetes	0.9	0.8	0.7	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2
Hypertension	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Glomerulonephritis	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.5
Other cause	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
All	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
ADJUSTED																						
0-19	1.9	1.9	2.0	1.9	2.3	2.1	1.8	1.9	2.1	1.9	2.0	2.2	1.8	2.2	1.8	1.7	1.6	1.8	1.9	1.7	1.7	1.8
20-44	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3
45-64	0.5	0.5	0.4	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2
65-74	0.8	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
75+	1.5	1.4	1.2	1.1	1.0	0.9	0.8	0.7	0.7	0.6	0.7	0.6	0.5	0.5	0.4	0.5	0.4	0.4	0.4	0.3	0.4	0.4
Male	0.6	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Female	0.5	0.6	0.5	0.5	0.5	0.4	0.3	0.4	0.3	0.3	0.3	0.3	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2
White	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Black	0.7	0.6	0.6	0.5	0.6	0.5	0.5	0.4	0.4	0.4	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Other race	2.3	2.0	2.0	1.8	1.5	1.4	1.3	1.3	1.3	1.1	0.9	0.9	0.9	0.8	0.8	0.7	0.6	0.6	0.6	0.6	0.5	0.6
Diabetes	1.0	0.8	0.8	0.7	0.6	0.6	0.6	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2
Hypertension	0.9	0.8	0.6	0.6	0.6	0.5	0.5	0.4	0.5	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.3	0.3
Glomerulonephritis	0.9	0.8	0.8	0.7	0.7	0.7	0.7	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.5	0.5	0.5	0.4	0.5
Other cause	0.5	0.5	0.5	0.5	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
All	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1

Table I.13
Two-year Survival Probabilities: Incident Dialysis Patients

censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	80.1	88.3	83.7	79.0	82.9	78.5	81.6	78.3	70.2	74.4	71.3	77.1	85.3	78.2	79.5	76.8	84.4	77.8	83.3	85.5	75.7
5-9	87.6	95.6	90.2	88.2	83.1	88.7	82.5	100.0	100.0	95.7	88.1	94.8	94.4	92.9	97.0	98.4	90.7	95.8	93.8	95.6	98.1
10-14	95.6	93.9	92.8	96.0	90.2	95.6	94.8	98.8	92.3	95.3	88.9	95.9	91.0	90.1	94.7	94.4	93.7	93.5	95.6	95.9	94.1
15-19	94.0	89.3	91.6	89.5	92.5	91.0	88.5	92.7	93.5	95.8	94.0	91.5	94.4	91.8	93.1	95.2	90.2	92.2	91.2	92.8	90.9
20-29	81.8	84.0	84.1	82.1	83.4	79.7	84.0	80.9	84.7	84.9	83.6	84.1	86.0	86.4	87.4	85.5	88.5	89.5	90.7	89.5	87.5
30-39	78.1	79.5	77.0	79.3	75.3	74.6	75.6	76.1	78.7	77.8	78.7	77.5	78.8	79.9	79.3	80.8	81.6	83.3	82.0	83.6	83.7
40-49	76.1	75.1	74.9	74.6	74.3	74.5	73.7	73.8	75.6	75.5	78.1	74.2	76.7	77.4	77.9	78.9	78.5	79.4	79.4	79.4	79.9
50-59	70.1	69.8	70.1	67.3	66.3	66.0	66.3	66.3	67.3	68.6	69.0	68.9	70.3	71.5	72.6	71.9	72.2	72.6	71.6	72.8	72.7
60-64	63.1	60.5	60.4	60.9	58.2	58.1	59.6	58.4	59.3	60.1	60.7	61.7	62.1	64.7	65.0	64.0	65.8	65.8	64.2	66.2	66.4
65-69	54.9	55.7	55.1	52.1	55.0	52.8	53.7	55.3	55.7	55.7	56.1	56.5	57.7	59.8	58.6	59.3	60.5	58.9	58.9	59.3	60.4
70-79	46.6	48.6	48.9	44.1	46.4	46.9	46.4	45.5	46.4	47.6	47.8	48.0	49.0	49.9	50.3	50.6	51.6	49.8	50.8	50.8	50.4
80+	31.4	34.7	38.2	30.0	36.5	35.9	35.3	33.0	33.3	37.4	36.9	35.9	36.6	37.6	38.6	38.4	38.5	37.0	37.0	37.1	37.2
Male	64.4	65.4	64.1	60.2	60.6	58.5	59.1	58.6	59.6	60.5	60.7	60.1	61.0	62.7	62.4	62.5	62.6	61.5	61.6	62.0	62.0
Female	66.8	66.2	65.7	61.9	62.2	62.0	61.4	60.3	61.5	61.4	61.4	60.5	61.6	62.0	62.2	62.0	62.3	60.9	60.5	60.5	60.1
White	63.5	63.8	62.1	57.9	57.7	56.7	56.4	55.8	56.0	56.5	56.5	55.8	56.6	57.5	57.6	57.6	57.8	56.3	56.8	57.1	56.9
Black	68.8	69.8	70.4	67.0	68.7	67.1	68.0	67.1	69.4	68.9	69.6	68.4	69.7	71.1	70.6	70.5	71.1	70.5	69.1	69.0	69.2
Other race	66.9	62.6	68.1	62.8	61.5	60.1	60.2	58.1	62.9	68.0	67.6	71.0	70.1	71.6	71.1	68.3	68.1	68.3	65.7	68.9	69.6
†Hispanic																	67.6	67.1	67.8	68.5	70.5
†Non-Hispanic																	61.8	60.5	60.2	60.4	59.9
Diabetes	54.9	52.9	51.1	52.9	50.9	51.2	52.4	53.1	55.2	56.6	56.1	56.8	57.7	59.9	60.0	59.7	60.0	59.4	58.9	60.1	60.3
Hypertension	69.7	66.6	64.5	61.2	62.3	60.9	60.4	58.7	60.3	60.2	60.1	59.3	60.3	60.7	61.2	61.7	62.1	60.0	59.8	59.7	59.6
Glomerulonephritis	79.4	76.1	74.7	73.1	74.3	72.1	71.0	71.0	72.8	72.2	72.9	71.2	73.6	75.3	74.0	75.0	75.2	74.1	76.0	75.2	75.3
Other cause	63.6	67.7	70.1	61.3	63.3	62.3	63.1	62.0	61.4	62.6	64.4	62.5	63.4	63.2	62.7	61.9	62.1	61.7	61.3	60.4	59.6
All	65.5	65.8	64.9	61.0	61.3	60.1	60.2	59.4	60.5	60.9	61.0	60.3	61.3	62.4	62.3	62.2	62.5	61.2	61.1	61.3	61.2
ADJUSTED																					
0-19	87.5	83.4	84.0	81.1	80.9	82.1	79.6	86.8	82.4	87.1	81.3	82.5	86.1	81.5	85.6	86.3	82.9	83.3	84.6	86.9	81.9
20-44	74.9	77.5	76.6	76.8	75.2	74.0	75.6	75.2	77.9	77.3	78.5	76.5	78.3	78.5	79.5	79.8	81.1	82.6	81.7	82.5	82.7
45-64	65.4	64.2	65.0	63.8	62.6	62.7	63.7	63.3	64.6	66.2	67.2	67.2	68.4	70.4	71.1	70.9	71.7	72.2	71.3	72.7	72.9
65-74	49.7	51.6	52.7	47.9	51.0	49.7	50.5	51.4	52.5	52.9	53.4	53.8	55.2	56.5	56.1	57.3	58.2	56.8	57.4	57.9	58.1
75+	37.8	41.1	39.7	35.3	39.5	40.5	39.9	37.7	38.3	41.6	41.3	41.3	41.7	42.9	43.6	43.1	44.4	42.6	43.2	43.3	43.3
Male	55.5	56.8	56.6	53.8	54.7	53.6	55.0	54.5	55.8	57.5	58.1	58.1	59.2	61.3	61.4	61.8	62.8	62.4	62.6	63.5	63.7
Female	58.3	58.2	59.1	56.6	57.4	57.9	58.0	57.9	59.2	60.0	60.6	60.3	61.6	62.1	62.8	63.1	64.0	63.2	63.0	63.3	63.3
White	54.3	55.1	54.8	52.0	52.6	52.6	53.0	53.1	53.8	55.5	55.9	55.9	57.1	58.3	58.9	59.4	60.4	59.7	60.4	61.0	61.0
Black	62.3	62.3	63.3	61.2	62.8	61.6	63.1	62.2	64.4	64.3	65.4	64.6	66.1	67.6	67.5	67.5	68.5	68.3	66.9	66.9	67.4
Other race	58.4	55.5	59.7	56.6	55.8	55.9	57.3	55.3	60.3	66.1	66.0	69.8	68.7	70.7	70.2	68.6	68.8	69.7	66.9	70.6	71.0
Diabetes	48.1	46.1	45.2	47.2	45.9	46.5	48.3	49.3	51.7	53.6	53.6	54.6	55.8	58.2	58.6	58.6	59.4	59.2	58.9	60.3	60.8
Hypertension	64.6	62.8	61.9	59.8	61.3	61.1	61.4	60.2	61.9	62.4	62.7	62.5	63.3	64.1	64.8	65.4	66.3	64.8	65.1	65.1	65.2
Glomerulonephritis	71.1	68.4	67.8	66.8	68.5	67.4	66.4	66.5	67.9	68.1	69.0	67.5	69.9	71.8	71.2	71.8	72.8	72.0	73.2	73.2	73.4
Other cause	59.1	62.3	65.3	58.7	60.3	59.4	60.5	59.7	59.0	60.6	62.3	60.9	62.0	61.8	61.7	61.1	61.6	61.8	61.3	61.1	60.3
All	56.8	57.5	57.8	55.1	56.0	55.6	56.4	56.1	57.4	58.7	59.3	59.1	60.3	61.7	62.1	62.4	63.3	62.8	62.8	63.4	63.5

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.14
Five-year Survival Probabilities: Incident Dialysis Patients

censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
0-4	80.1	75.8	83.7	66.7	65.9	64.8	64.8	65.4	64.4	69.5	53.5	64.9	73.0	59.0	69.0	64.0	71.3	67.7
5-9	87.6	95.6	68.7	78.4	83.1	66.5	74.3	83.3	91.7	74.4	78.0	94.8	80.2	78.0	85.3	88.6	86.1	95.8
10-14	80.6	74.3	83.6	92.9	86.7	88.5	80.2	82.1	74.1	86.8	79.9	78.8	79.6	79.6	75.1	84.5	83.2	84.0
15-19	88.5	79.6	77.1	84.6	84.2	69.9	75.1	80.3	74.7	78.0	84.4	82.8	85.1	79.4	79.8	84.9	80.8	83.1
20-29	72.6	66.2	67.0	62.3	61.1	58.4	65.4	61.6	67.4	63.2	66.5	66.1	68.2	70.0	71.6	71.3	73.2	74.6
30-39	58.8	58.6	52.3	54.6	52.7	50.1	51.0	48.6	54.5	54.9	54.5	53.6	55.7	58.0	57.2	59.2	60.4	62.0
40-49	51.7	49.6	49.0	45.8	47.6	46.4	46.5	46.8	48.6	45.9	47.8	47.1	48.3	49.7	50.6	52.5	51.1	52.3
50-59	39.4	39.5	38.8	36.2	34.9	33.6	35.2	35.8	35.0	35.4	35.2	36.8	36.8	39.1	39.3	39.5	39.0	39.9
60-64	30.7	30.3	28.1	28.0	25.7	25.8	27.0	25.7	27.6	26.9	27.4	27.7	28.3	29.8	30.4	29.3	30.7	31.9
65-69	23.3	24.5	24.0	20.6	22.1	22.1	21.8	22.6	22.5	22.4	22.6	21.5	23.5	23.7	24.5	24.1	25.0	24.2
70-79	15.8	15.8	16.9	13.7	15.2	15.6	15.0	15.5	15.5	16.0	15.6	15.8	15.8	16.6	16.5	17.1	17.8	16.9
80+	8.5	7.5	7.3	6.4	7.8	8.3	7.5	7.9	6.9	9.0	8.8	7.7	7.6	8.0	8.2	8.9	9.0	8.1
Male	35.9	34.4	32.8	28.8	28.6	26.9	27.7	27.7	28.5	28.8	28.5	28.1	28.5	30.0	29.8	30.6	30.3	29.4
Female	37.8	38.1	35.4	31.5	31.5	30.7	30.3	29.5	30.1	28.8	29.0	28.2	28.9	29.2	29.4	29.2	29.1	28.8
White	35.3	33.1	30.9	26.6	26.3	25.0	24.6	24.0	23.7	23.4	23.1	22.6	22.9	23.5	23.7	23.6	23.7	22.7
Black	39.7	42.1	40.4	36.4	37.5	36.3	37.6	37.1	39.5	38.4	39.2	38.4	39.1	40.3	40.0	41.3	40.7	40.8
Other race	32.2	30.3	37.1	33.7	27.0	26.7	28.3	31.8	33.7	35.1	34.5	36.0	37.7	39.6	39.2	35.0	35.5	36.5
†Hispanic	35.3	34.3
†Non-Hispanic	29.0	28.5
Diabetes	24.2	21.6	18.8	19.4	18.4	17.8	20.1	20.1	21.6	21.1	21.1	21.8	22.7	24.0	24.5	24.2	24.4	24.3
Hypertension	42.5	37.1	34.5	32.0	31.2	30.5	29.8	28.7	30.1	29.3	29.9	28.2	28.8	29.0	29.3	30.7	30.7	29.7
Glomerulonephritis	54.5	49.3	45.9	43.5	42.9	39.4	39.7	40.5	42.1	41.4	42.1	42.4	43.5	45.2	44.9	46.5	45.7	44.6
Other cause	34.4	38.3	39.4	30.6	33.2	33.0	33.1	33.1	32.2	34.0	33.4	33.0	33.1	34.4	33.6	33.9	34.0	33.9
All	36.7	36.2	34.1	30.1	30.0	28.8	29.0	28.6	29.3	28.8	28.7	28.2	28.7	29.6	29.6	29.9	29.7	29.1
ADJUSTED																		
0-19	76.4	65.4	65.3	73.0	69.8	57.7	61.4	66.8	61.1	66.3	66.3	67.5	70.4	62.5	64.7	70.4	69.2	70.7
20-44	55.1	54.1	51.5	49.9	50.6	47.6	51.2	49.2	52.8	52.2	53.5	51.9	53.8	55.0	56.2	57.1	57.7	59.1
45-64	33.4	33.1	32.9	31.2	30.2	29.9	31.7	31.5	32.5	32.8	33.3	34.8	35.1	37.4	38.1	38.5	39.0	40.4
65-74	18.4	19.6	20.1	16.7	18.5	18.8	18.4	19.6	19.9	20.2	20.5	19.7	21.4	21.7	22.2	22.5	23.6	22.7
75+	10.6	10.5	10.7	8.4	10.1	10.7	10.7	10.4	9.9	11.7	10.7	11.2	10.3	11.3	11.1	12.1	12.6	12.0
Male	27.1	26.4	26.4	23.8	24.4	24.1	25.3	25.3	26.0	27.4	27.1	27.6	27.9	29.7	29.9	30.8	31.7	31.3
Female	29.1	30.0	29.3	27.2	28.0	28.0	28.4	28.6	29.1	28.9	29.5	29.5	30.5	30.9	31.5	31.8	32.5	32.7
White	26.3	25.2	24.9	22.6	23.2	23.2	23.6	23.6	23.8	24.8	24.6	24.8	25.5	26.5	27.1	27.5	28.7	28.3
Black	32.1	33.6	32.4	30.3	31.4	30.8	32.6	32.4	34.1	33.5	34.7	34.6	35.2	36.5	36.6	38.0	37.8	38.3
Other race	24.8	25.3	29.0	28.8	23.8	25.6	27.5	30.3	32.2	34.9	34.1	36.8	37.6	39.6	39.6	36.7	37.7	39.7
Diabetes	19.4	17.3	15.7	16.3	16.2	16.0	18.1	18.5	19.7	19.9	20.0	21.1	22.0	23.4	24.2	24.1	24.8	25.0
Hypertension	37.1	33.5	33.0	31.8	31.7	32.2	32.4	32.1	33.0	33.1	34.0	33.1	33.4	34.0	34.5	35.8	36.5	36.0
Glomerulonephritis	43.2	40.3	38.8	37.6	38.0	36.0	36.4	36.9	38.0	38.3	38.6	39.6	40.2	41.7	42.2	42.9	43.4	42.7
Other cause	30.4	33.1	35.0	28.9	31.4	31.3	31.8	31.8	31.0	33.3	32.4	32.5	32.9	33.9	33.5	33.8	34.4	34.9
All	28.0	28.0	27.7	25.4	26.1	25.9	26.7	26.8	27.4	28.1	28.2	28.4	29.1	30.2	30.7	31.3	32.0	32.0

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.15
Ten-year Survival Probabilities: Incident Dialysis Patients

censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	80.1	65.0	55.8	40.0	54.9	25.9	64.8	56.1	41.6	69.5	36.7	59.0	63.9
5-9	87.6	65.6	51.5	78.4	83.1	44.4	74.3	83.3	91.7	59.5	62.4	35.5	70.2
10-14	59.6	49.5	58.9	76.0	69.5	81.1	59.4	82.1	52.7	57.8	57.3	70.9	65.7
15-19	80.0	60.6	63.5	69.5	60.2	53.8	55.6	57.0	60.3	66.5	64.0	64.7	60.7
20-29	52.1	45.0	44.9	42.1	41.4	41.7	43.0	40.3	44.6	40.6	44.9	42.1	46.3
30-39	37.0	34.7	29.6	32.0	30.5	29.1	28.4	27.7	28.9	30.7	31.1	30.0	32.3
40-49	25.0	22.8	21.9	21.0	22.6	20.6	20.2	20.9	22.4	18.8	20.0	19.4	20.7
50-59	12.6	13.4	13.2	11.2	10.9	11.5	10.8	11.1	10.3	10.3	10.3	10.8	10.5
60-64	7.4	7.4	5.4	7.0	6.7	7.1	6.9	5.8	6.5	5.6	5.3	5.6	6.2
65-69	4.6	5.2	4.0	4.8	4.9	5.7	4.7	4.2	4.2	4.1	4.4	3.8	4.1
70-79	2.5	2.0	2.7	2.0	2.8	2.7	2.3	2.5	2.3	1.9	1.9	1.7	2.0
80+	2.5	1.8	2.6	0.6	1.7	1.2	0.9	0.9	0.5	0.7	0.4	0.6	0.5
Male	13.2	11.9	10.6	9.6	9.8	9.4	9.3	9.0	8.8	8.4	8.9	8.0	8.6
Female	14.9	14.5	12.3	11.0	10.9	10.5	9.5	8.9	9.5	8.4	7.9	7.9	8.0
White	13.6	11.5	10.0	8.5	8.7	7.9	7.3	6.8	6.4	5.6	5.7	5.3	5.4
Black	15.0	16.2	14.2	13.5	13.6	13.9	13.3	12.7	14.2	13.6	13.3	12.9	13.6
Other race	9.7	11.3	12.0	10.9	9.9	8.8	11.2	10.5	11.2	10.0	11.9	11.1	12.3
Diabetes	6.9	5.2	4.3	4.1	4.2	4.2	4.1	4.1	4.4	3.9	4.1	3.9	4.1
Hypertension	16.9	14.3	11.0	11.0	10.6	10.0	9.6	8.3	9.2	8.8	8.5	8.1	8.7
Glomerulonephritis	29.3	21.5	17.3	17.5	18.2	16.9	16.4	16.2	16.8	15.7	17.1	16.6	18.3
Other cause	11.9	13.7	14.5	11.3	12.2	12.8	12.2	12.5	12.0	11.8	12.2	11.8	12.0
All	14.0	13.1	11.4	10.3	10.3	9.9	9.4	8.9	9.1	8.4	8.4	8.0	8.3
ADJUSTED													
0-19	62.6	44.0	45.3	54.3	46.6	40.0	43.2	47.9	45.2	52.1	45.0	48.8	48.4
20-44	32.5	29.4	26.8	27.0	27.8	26.6	27.2	26.1	27.6	27.5	28.5	27.1	29.0
45-64	9.5	9.7	9.5	8.8	9.0	9.3	9.3	9.3	9.4	9.0	9.3	9.8	10.3
65-74	3.1	3.3	3.1	3.2	3.7	4.2	3.6	3.4	3.3	3.3	3.5	3.1	3.5
75+	1.7	1.4	2.0	0.8	1.7	1.4	1.3	1.5	1.2	1.0	0.7	1.0	0.9
Male	9.2	8.6	8.6	8.1	8.7	9.2	9.1	8.9	8.5	8.6	9.1	8.8	9.2
Female	10.7	10.9	10.3	9.8	10.4	10.4	9.8	9.9	10.3	9.8	9.7	9.9	10.3
White	9.4	8.5	8.3	7.7	8.5	8.6	8.3	8.2	7.8	7.7	7.9	7.9	8.3
Black	10.8	11.4	10.5	10.4	10.8	11.3	10.8	10.9	11.7	11.2	11.4	11.3	11.7
Other race	7.1	9.5	10.9	10.0	9.6	9.8	11.9	11.2	11.6	11.9	12.6	13.2	13.9
Diabetes	5.3	4.3	4.0	3.8	4.1	4.4	4.1	4.3	4.4	4.0	4.4	4.3	4.5
Hypertension	14.7	13.4	11.8	12.2	12.4	12.4	12.4	11.9	12.0	11.9	11.7	11.6	12.2
Glomerulonephritis	20.1	16.1	14.7	14.8	16.3	16.3	15.5	15.1	15.3	14.7	15.5	15.6	16.8
Other cause	10.9	12.0	13.0	11.2	12.4	13.0	12.4	12.6	12.1	12.4	12.4	12.6	12.8
All	9.9	9.6	9.4	8.8	9.5	9.7	9.4	9.3	9.3	9.1	9.3	9.3	9.7

The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Includes U.S. & territories; no unknown or foreign states.

Standard Errors

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	10.2	12.2	19.0	14.0	12.9	12.6	9.7	11.0	9.7	7.3	11.0	8.7	8.3
5-9	5.9	16.2	16.2	10.5	6.9	17.3	10.2	10.3	7.6	15.7	14.0	19.9	12.2
10-14	8.0	10.7	10.0	9.1	9.4	8.3	13.4	7.6	13.5	12.0	11.4	9.4	9.9
15-19	3.7	4.7	6.3	5.2	6.9	6.1	5.7	5.7	5.4	4.7	5.3	5.0	5.5
20-29	2.4	2.4	2.4	2.3	2.2	2.3	2.1	2.1	2.1	2.0	1.9	1.9	1.8
30-39	1.7	1.6	1.5	1.5	1.5	1.4	1.3	1.3	1.2	1.1	1.1	1.1	1.0
40-49	1.2	1.1	1.1	1.0	1.1	1.0	0.9	0.9	0.9	0.8	0.7	0.7	0.7
50-59	0.6	0.6	0.6	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4
60-64	0.6	0.6	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3
65-69	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.2	0.2
70-79	0.3	0.3	0.3	0.2	0.3	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1
80+	0.8	0.7	0.7	0.3	0.4	0.3	0.2	0.2	0.2	0.2	0.1	0.1	0.1
Male	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2
Female	0.5	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2
White	0.4	0.4	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.1
Black	0.6	0.6	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3
Other race	1.5	1.6	1.8	1.4	1.3	1.1	1.2	1.0	1.0	1.0	1.0	0.9	0.9
Diabetes	0.6	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Hypertension	0.8	0.6	0.5	0.5	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
Glomerulonephritis	1.3	1.1	0.9	0.9	0.8	0.8	0.8	0.7	0.7	0.7	0.7	0.7	0.7
Other cause	0.4	0.5	0.5	0.4	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4
All	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1
ADJUSTED													
0-19	4.9	4.8	6.1	5.6	5.8	4.9	5.1	5.3	4.9	4.6	5.1	4.9	5.3
20-44	1.0	1.0	0.9	0.9	0.9	0.8	0.9	0.8	0.7	0.7	0.7	0.6	0.6
45-64	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
65-74	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1
75+	0.4	0.3	0.4	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1
Male	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Female	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2
White	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Black	0.4	0.4	0.4	0.3	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.2	0.2
Other race	0.8	1.1	1.4	1.2	0.9	0.9	1.0	0.8	0.9	0.9	0.8	0.8	0.8
Diabetes	0.4	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Hypertension	0.6	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3
Glomerulonephritis	0.9	0.8	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.5	0.6	0.5	0.5
Other cause	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.4	0.3	0.3
All	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1